#Coronavirus Disease Research #References (by AMEDEO, May 11 ’24)

1. MONZON R, Ornelas-Dorian C, Eucker SA, Rising K, et al
   An evaluation of COVID-19 vaccine messaging platforms in the emergency department.
   Acad Emerg Med. 2024 May 5. doi: 10.1111/acem.14933.
   PubMed        
   
   
   Antiviral Res
2. SALGADO-BENVINDO C, Tas A, Zevenhoven-Dobbe JC, van der Meer Y, et al
   Characterization of SARS-CoV-2 replication in human H1299/ACE2 cells: a versatile and practical infection model for antiviral research and beyond.
   Antiviral Res. 2024 May 7:105903. doi: 10.1016/j.antiviral.2024.105903.
   PubMed         Abstract available
   
   
   BMJ
3. 
   Seven days in medicine: 1-7 May 2024.
   BMJ. 2024;385:q1022.
   PubMed        
   
4. MAHASE E
   Workforce and winter under Labour: Wes Streeting on his plan for the NHS and ending the strikes.
   BMJ. 2024;385:q992.
   PubMed        
   
5. WONG G, Kelly M
   NHS funding for a secure future: naming the elephant in the room.
   BMJ. 2024;385:q1036.
   PubMed        
   
6. NAKWEYA G
   Moderna’s decision to shelve vaccine plant in Kenya should encourage global south’s self-reliance, says global health adviser.
   BMJ. 2024;385:q1051.
   PubMed        
   
7. MAFI A
   Doctors in training should be at the top of the workforce priority list.
   BMJ. 2024;385:q1045.
   PubMed        
   
8. WATERS A
   LMC removes GP from committee amid row over attendance at meetings.
   BMJ. 2024;385:q1021.
   PubMed        
   
9. LOOI MK
   Why WHO changed the definition of “airborne transmission” in the wake of the pandemic.
   BMJ. 2024;385:q985.
   PubMed        
   
10. LYNN E
    April top picks: Hope springs eternal.
    BMJ. 2024;385:q1037.
    PubMed        
    
    
    Clin Infect Dis
11. ANDREWS JS, Boonyaratanakornkit JB, Krusinska E, Allen S, et al
    Assessment of the Impact of RNase in Patients With Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2 Infection (PASC): A Randomized Phase 2 Trial of RSLV-132.
    Clin Infect Dis. 2024 May 10:ciae205. doi: 10.1093.
    PubMed         Abstract available
    
    
    Int J Infect Dis
12. XIANG Y, Feng Y, Qiu J, Zhang R, et al
    Association of COVID-19 vaccination with risks of hospitalization due to cardiovascular and other diseases: a study using data from the UK Biobank.
    Int J Infect Dis. 2024 May 1:107080. doi: 10.1016/j.ijid.2024.107080.
    PubMed         Abstract available
    
13. SCOTT AJ, Limbada M, Perumal T, Jaumdally S, et al
    Integrating molecular and radiological screening tools during community-based active case-finding for tuberculosis and COVID-19 in southern Africa.
    Int J Infect Dis. 2024 May 1:107081. doi: 10.1016/j.ijid.2024.107081.
    PubMed         Abstract available
    
14. VAN VOORDEN J, de Groot CJM, Ris-Stalpers C, Afink GB, et al
    Corrigendum to “COVID-19 mRNA vaccination during pregnancy does not harm syncytiotrophoblast development” [International Journal of Infectious Diseases, 140C (2024) pages 95-98].
    Int J Infect Dis. 2024;144:107068.
    PubMed        
    
15. LIN DY, Xu Y, Gu Y, Sunny SK, et al
    Impact of Booster Vaccination Interval on SARS-CoV-2 Infection, Hospitalization, and Death.
    Int J Infect Dis. 2024 May 3:107084. doi: 10.1016/j.ijid.2024.107084.
    PubMed         Abstract available
    
    
    Intensive Care Med
16. MONTOMOLI J, Vergano M, Semeraro F, Bignami EG, et al
    From the pandemic to a war: a call for solidarity with all healthcare workers.
    Intensive Care Med. 2024;50:776-777.
    PubMed        
    
17. DE CORTE T, Kohler K, Cecconi M, De Waele JJ, et al
    Characteristics of co-infection and secondary infection amongst critically ill COVID-19 patients in the first two waves of the pandemic.
    Intensive Care Med. 2024 May 6. doi: 10.1007/s00134-024-07444.
    PubMed        
    
    
    Invest Radiol
18. ECKSTEIN J, Skeries V, Pohler G, Babazade N, et al
    Multiparametric Cardiovascular MRI Assessment of Post-COVID Syndrome in Children in Comparison to Matched Healthy Individuals.
    Invest Radiol. 2024;59:472-478.
    PubMed         Abstract available
    
    
    J Infect
19. KIRSEBOM FCM, Stowe J, Lopez Bernal J, Allen A, et al
    Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study.
    J Infect. 2024 May 6:106177. doi: 10.1016/j.jinf.2024.106177.
    PubMed         Abstract available
    
20. HALVORSEN B, Viermyr HK, Ueland T, Sagen EL, et al
    IL-22 is increased in hospitalized patients with COVID-19 and associates with cardiac involvement.
    J Infect. 2024 May 6:106176. doi: 10.1016/j.jinf.2024.106176.
    PubMed        
    
    
    J Med Virol
21. FENG Y, Zhao X, Chen Z, Wu Y, et al
    Prevalence and diversity of imported severe acute respiratory syndrome coronavirus 2 variants in China, 2021-2022.
    J Med Virol. 2024;96:e29664.
    PubMed         Abstract available
    
22. ISHII T, Nawa N, Hosokawa S, Morio T, et al
    Exploring viral infections’ role in Kawasaki disease onset: A study during the COVID-19 pandemic.
    J Med Virol. 2024;96:e29660.
    PubMed         Abstract available
    
23. ASHOKKUMAR S, Lim JS, Kaushik NK, Han I, et al
    Human coronavirus 229E inactivation on porous and nonporous materials using dielectric barrier discharge (DBD) plasma.
    J Med Virol. 2024;96:e29655.
    PubMed         Abstract available
    
24. WU JY, Chen CC, Liu MY, Hsu WH, et al
    Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.
    J Med Virol. 2024;96:e29662.
    PubMed         Abstract available
    
25. CHENG P, Zhai K, Han W, Zeng J, et al
    Characterizing the antigenic evolution of pandemic influenza A (H1N1) pdm09 from 2009 to 2023.
    J Med Virol. 2024;96:e29657.
    PubMed         Abstract available
    
26. CHEN SY, Hsieh TYJ, Hung YM, Oh JW, et al
    Prior COVID-19 vaccination and reduced risk of cerebrovascular diseases among COVID-19 survivors.
    J Med Virol. 2024;96:e29648.
    PubMed         Abstract available
    
27. RZYMSKI P, Zarebska-Michaluk D, Parczewski M, Genowska A, et al
    The burden of infectious diseases throughout and after the COVID-19 pandemic (2020-2023) and Russo-Ukrainian war migration.
    J Med Virol. 2024;96:e29651.
    PubMed         Abstract available
    
28. GRUBER CEM, Tucci FG, Giombini E, Mazzotta V, et al
    Molnupiravir increases SARS-CoV-2 genome diversity and complexity: A case-control cohort study.
    J Med Virol. 2024;96:e29642.
    PubMed         Abstract available
    
    
    J Virol
29. ADAIR A, Tan LL, Feng J, Girkin J, et al
    Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection.
    J Virol. 2024 May 6:e0053124. doi: 10.1128/jvi.00531.
    PubMed         Abstract available
    
30. YU M, Li J, Gao W, Li Z, et al
    Multiple E3 ligases act as antiviral factors against SARS-CoV-2 via inducing the ubiquitination and degradation of ORF9b.
    J Virol. 2024 May 6:e0162423. doi: 10.1128/jvi.01624.
    PubMed         Abstract available
    
    
    JAMA
31. HARRIS E
    National Academies Report: COVID-19 Vaccines Don’t Cause Many Potential Harms.
    JAMA. 2024 May 10. doi: 10.1001/jama.2024.7724.
    PubMed        
    
32. ANDERER S
    Could “Empathetic Refutation” Help Clinicians Sway Vaccine Skeptics?
    JAMA. 2024 Apr 12. doi: 10.1001/jama.2024.4493.
    PubMed        
    
33. AGRAWAL S, Ross JS, Ramachandran R
    Implications for Public Health Regulation if Chevron Deference Is Overturned.
    JAMA. 2024;331:1443-1444.
    PubMed        
    
34. HARRIS E
    Trials Will Evaluate Treatments for Long COVID Nervous System Problems.
    JAMA. 2024;331:1439-1440.
    PubMed        
    
    
    Lancet
35. KIVIMAKI M, Batty GD
    Work as a health risk.
    Lancet. 2024;403:1747-1748.
    PubMed        
    
    
    Lancet Infect Dis
36. WANG H, Wei Y, Hung CT, Lin G, et al
    Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study.
    Lancet Infect Dis. 2024 May 3:S1473-3099(24)00217.
    PubMed         Abstract available
    
37. ARES-GOMEZ S, Mallah N, Santiago-Perez MI, Pardo-Seco J, et al
    Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
    Lancet Infect Dis. 2024 Apr 30:S1473-3099(24)00215.
    PubMed         Abstract available
    
38. SORIANO V, Moreno-Torres V
    Oral antivirals for acute symptoms and post-acute sequelae in SARS-CoV-2 infection.
    Lancet Infect Dis. 2024 May 3:S1473-3099(24)00258.
    PubMed        
    
    
    Nature
39. DESAUTELS TA, Arrildt KT, Zemla AT, Lau EY, et al
    Computationally restoring the potency of a clinical antibody against Omicron.
    Nature. 2024 May 8. doi: 10.1038/s41586-024-07385.
    PubMed         Abstract available
    
    
    Science
40. THORP HH
    Mr. Thorp goes to Washington.
    Science. 2024;384:601.
    PubMed         Abstract available
    
41. COHEN J
    Virus gone wild.
    Science. 2024;384:615-617.
    PubMed         Abstract available
    
    
    Zhonghua Jie He He Hu Xi Za Zhi
42. YANG LL, Huang LT, Ren SY, Ouyang RY, et al
    [COVID-19 in patients with Good syndrome: report of 4 cases and literature review].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:430-436.
    PubMed         Abstract available
    
43. LIU MH, Sun YX, Li ZL, Zhang LJ, et al
    [Retrospective analysis of diagnosis and treatment of tuberculosis in designated medical institutions in China from 2017 to 2022].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:437-443.
    PubMed         Abstract available
    
44. GU SJ, Wen JL, Wang XY, Zhang LX, et al
    [Progress in the diagnose and treatment of pulmonary arterial thrombosis in situ].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:464-469.
    PubMed         Abstract available

#Coronavirus Disease Research #References (by Amedeo.com, May 4 ’24)

1. GRADY E, Pattison DA, Redman S, Satoh Y, et al
   The Global Reading Room: Performing a Ventilation-Perfusion Study in a Patient With Recent COVID-19.
   AJR Am J Roentgenol. 2024 May 1. doi: 10.2214/AJR.24.31348.
   PubMed        
   
   
   Am J Obstet Gynecol
2. MAGNUS MC, Rasmussen TD, Ortqvist AK, Oakley LL, et al
   Covid-19 vaccination during pregnancy is not associated with an increased risk of severe post-partum hemorrhage.
   Am J Obstet Gynecol. 2024 Apr 30:S0002-9378(24)00554.
   PubMed        
   
   
   Am J Respir Crit Care Med
3. AZOULAY E, Pochard F, Argaud L, Kentish-Barnes N, et al
   Reply to Zijlstra: Resilience and Stress Are Heterogenic Too, We Should Act Accordingly.
   Am J Respir Crit Care Med. 2024 May 3. doi: 10.1164/rccm.202404-0790.
   PubMed        
   
   
   Antiviral Res
4. LIU X, Wang Y, Sun L, Xiao G, et al
   Screening and optimization of shark nanobodies against SARS-CoV-2 Spike RBD.
   Antiviral Res. 2024 Apr 29:105898. doi: 10.1016/j.antiviral.2024.105898.
   PubMed         Abstract available
   
5. ARDUINO I, Francese R, Civra A, Feyles E, et al
   Polyoxometalate exerts broad-spectrum activity against human respiratory viruses hampering viral entry.
   Antiviral Res. 2024;226:105897.
   PubMed         Abstract available
   
6. AMERATUNGA R, Jordan A, Lehnert K, Leung E, et al
   SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
   Antiviral Res. 2024 Apr 25:105894. doi: 10.1016/j.antiviral.2024.105894.
   PubMed         Abstract available
   
   
   BMJ
7. SILLETT JM
   Perhaps politicians and health leaders could #sayhellotopatients?
   BMJ. 2024;385:q976.
   PubMed        
   
8. MATHEW R
   Rammya Mathew: We can’t overlook the backdrop as Britain becomes “a sicker nation”.
   BMJ. 2024;385:q956.
   PubMed        
   
9. WISE J
   MP resigns from Tory party over NHS “stretched close to breaking point”.
   BMJ. 2024;385:q983.
   PubMed        
   
10. MIDDLETON J, Saunders P
    What will it take for a new sanitary revolution in the UK?
    BMJ. 2024;385:q974.
    PubMed        
    
11. MORGAN SG
    When will Canada have national pharmacare?
    BMJ. 2024;385:q887.
    PubMed        
    
12. TANNE JH
    US pregnant workers get new legal protections, but not paid time off.
    BMJ. 2024;385:q926.
    PubMed        
    
13. MAHASE E
    Doctors will shape Labour’s 10 year plan to fix NHS crisis, says shadow health secretary.
    BMJ. 2024;385:q980.
    PubMed        
    
14. MCCARTNEY M, Liu PJ, Fearfull A, Macdonald H, et al
    Early diagnosis is not always an unmitigated good, we need to make it useful for patients and clinicians.
    BMJ. 2024;385:q973.
    PubMed        
    
15. 
    Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial.
    BMJ. 2024;385:q988.
    PubMed        
    
16. LANG K
    What do we know about covid-19’s effects on the gut?
    BMJ. 2024;385:q842.
    PubMed        
    
17. 
    Seven days in medicine: 24-30 April 2024.
    BMJ. 2024;385:q969.
    PubMed        
    
    
    Br J Anaesth
18. BOWDLE A, Brosseau LM, Tellier R, MacIntyre CR, et al
    Reducing airborne transmissible diseases in perioperative environments.
    Br J Anaesth. 2024 Apr 26:S0007-0912(24)00181-8. doi: 10.1016/j.bja.2024.
    PubMed         Abstract available
    
    
    Clin Infect Dis
19. JORGENSEN SCJ, Brown K, Clarke AE, Schwartz KL, et al
    The Effect of COVID-19 Vaccination on Outpatient Antibiotic Prescribing in Older Adults: A Self-Controlled Risk-Interval Study.
    Clin Infect Dis. 2024 May 3:ciae182. doi: 10.1093.
    PubMed         Abstract available
    
20. BRAMANTE CT, Beckman KB, Mehta T, Karger AB, et al
    Favorable Antiviral Effect of Metformin on Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of Coronavirus Disease 2019.
    Clin Infect Dis. 2024 May 1:ciae159. doi: 10.1093.
    PubMed         Abstract available
    
21. SIEDNER MJ, Sax PE
    Repurposing Revisited: Exploring the Role of Metformin for Treatment of Coronavirus Disease 2019.
    Clin Infect Dis. 2024 May 1:ciae154. doi: 10.1093.
    PubMed        
    
22. 
    Correction to: Impact of Seasonal Coronavirus Antibodies on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responses in Solid Organ Transplant Recipients.
    Clin Infect Dis. 2024 Apr 30:ciae164. doi: 10.1093.
    PubMed        
    
23. 
    Correction to: Differential Cytokine Signatures of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza Infection Highlight Key Differences in Pathobiology.
    Clin Infect Dis. 2024 Apr 30:ciae166. doi: 10.1093.
    PubMed        
    
    
    Int J Infect Dis
24. XIE H, Zhang J, Bai S, Lv M, et al
    The contributions of vaccination and natural infection to the production of neutralizing antibodies against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) prototype strain and variants.
    Int J Infect Dis. 2024 Apr 24:107060. doi: 10.1016/j.ijid.2024.107060.
    PubMed         Abstract available
    
25. MARTINEZ-FIERRO ML, Perez-Favila A, Alfaro SMZ, Oropeza-de Lara SA, et al
    Gene variants rs5182, rs2074192, and rs4343 in the Renin-Angiotensin-Aldosterone system are associated with symptom severity, higher odds of hospitalization, and death in COVID-19.
    Int J Infect Dis. 2024 Apr 30:107067. doi: 10.1016/j.ijid.2024.107067.
    PubMed         Abstract available
    
26. YAN X, Zhao X, Du Y, Wang H, et al
    Dynamics of anti-SARS-CoV-2 IgG antibody responses following breakthrough infection and the predicted protective efficacy: a longitudinal community-based population study in China.
    Int J Infect Dis. 2024 Apr 30:107075. doi: 10.1016/j.ijid.2024.107075.
    PubMed         Abstract available
    
27. MURRAY HC, Muleme M, Cooper D, McNamara BJ, et al
    Prevalence, risk factors and outcomes of secondary infections among hospitalised patients with COVID-19 or post-COVID-19 conditions in Victoria, 2020-2023.
    Int J Infect Dis. 2024 Apr 30:107078. doi: 10.1016/j.ijid.2024.107078.
    PubMed         Abstract available
    
    
    J Med Virol
28. ZHAO XJ, Liu XL, Liang YM, Zhang S, et al
    Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China.
    J Med Virol. 2024;96:e29640.
    PubMed         Abstract available
    
29. TANG Z, Mao Y, Ruan P, Li J, et al
    Drugs targeting CMPK2 inhibit pyroptosis to alleviate severe pneumonia caused by multiple respiratory viruses.
    J Med Virol. 2024;96:e29643.
    PubMed         Abstract available
    
30. MATUSALI G, Mazzotta V, Meschi S, Colavita F, et al
    JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV.
    J Med Virol. 2024;96:e29631.
    PubMed        
    
31. GAO R, Feng C, Sheng Z, Li F, et al
    Research progress in Fc-effector functions against SARS-CoV-2.
    J Med Virol. 2024;96:e29638.
    PubMed         Abstract available
    
32. WANG F, Gao Y, Wagner AL, Lu Y, et al
    A systematic review and meta-analysis of herpes zoster occurrence/recurrence after COVID-19 infection and vaccination.
    J Med Virol. 2024;96:e29629.
    PubMed         Abstract available
    
33. THOMAS S, Smatti MK, Alsulaiti H, Zedan HT, et al
    Antibody-dependent enhancement (ADE) of SARS-CoV-2 in patients exposed to MERS-CoV and SARS-CoV-2 antigens.
    J Med Virol. 2024;96:e29628.
    PubMed         Abstract available
    
    
    Lancet
34. GREEN A
    Tobias Welte.
    Lancet. 2024;403:1626.
    PubMed        
    
35. ADEPOJU P
    Moderna stalls on African vaccine manufacturing plans.
    Lancet. 2024;403:1617.
    PubMed        
    
36. MARCHALIK D, Rehm D
    On not cutting corners.
    Lancet. 2024;403:1623.
    PubMed        
    
    
    Lancet Infect Dis
37. KEDDY KH, Tadesse BT
    Inaccessible: health, wealth, governance, and equity in low-income and middle-income countries.
    Lancet Infect Dis. 2024;24:444-445.
    PubMed        
    
38. KOCHER K, Moosmann C, Drost F, Schulein C, et al
    Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual.
    Lancet Infect Dis. 2024;24:e272-e274.
    PubMed        
    
39. LIN DY, Huang S, Milinovich A, Duggal A, et al
    Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA.
    Lancet Infect Dis. 2024;24:e278-e280.
    PubMed        
    
40. DE AMBROGI M
    A summer cold.
    Lancet Infect Dis. 2024;24:461.
    PubMed        
    
41. KAZI F, Mushtaq A
    Nuria Izquierdo-Useros-fighting the good fight.
    Lancet Infect Dis. 2024;24:458.
    PubMed        
    
42. MOODY J
    On the frontline during the COVID-19 pandemic.
    Lancet Infect Dis. 2024;24:464.
    PubMed        
    
43. VISSER LG
    Identifying efficacious SARS-CoV-2 antivirals in a changing immune landscape.
    Lancet Infect Dis. 2024 Apr 24:S1473-3099(24)00254.
    PubMed        
    
44. WONGNAK P, Schilling WHK, Jittamala P, Boyd S, et al
    Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).
    Lancet Infect Dis. 2024 Apr 24:S1473-3099(24)00183.
    PubMed         Abstract available
    
45. VENKATESAN P
    Tobias Welte.
    Lancet Infect Dis. 2024;24:457.
    PubMed        
    
    
    MMWR Morb Mortal Wkly Rep
46. XIE AG, Yomogida K, Berry I, Briggs NL, et al
    Notes from the Field: Increase in Nontoxigenic Corynebacterium diphtheriae – Washington, 2018-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:405-407.
    PubMed        
    
    
    Nature
47. CALLAWAY E
    Scientists tried to give people COVID – and failed.
    Nature. 2024 May 1. doi: 10.1038/d41586-024-01284.
    PubMed        
    
48. MALLAPATY S
    Chinese virologist who was first to share COVID-19 genome sleeps on street after lab shuts.
    Nature. 2024 May 1. doi: 10.1038/d41586-024-01293.
    PubMed        
    
49. LENHARO M, Wolf L
    Controversial virus-hunting scientist skewered at US COVID-origins hearing.
    Nature. 2024 May 1. doi: 10.1038/d41586-024-01305.
    PubMed        
    
    
    Radiology
50. SUTHAR PP, Hughes K, Mafraji M, Akyuz M, et al
    Case 324: CHANTER Syndrome.
    Radiology. 2024;311:e222748.
    PubMed         Abstract available
    
    
    Science
51. CICERO A, Phelan A
    A pandemic agreement is within reach.
    Science. 2024;384:489.
    PubMed         Abstract available
    
52. LYNTERIS C
    Pandemics and their accelerantsThe Human Disease: How We Create Pandemics, from Our Bodies to Our Beliefs Sabrina Sholts MIT Press, 2024. 352 pp.
    Science. 2024;384:517.
    PubMed         Abstract available

#Coronavirus Disease Research #References (by Amedeo.com, April 27 ’24)

1. PAXTON JH, Keenan KJ, Wilburn JM, Wise SL, et al
   Headpulse measurement can reliably identify large-vessel occlusion stroke in prehospital suspected stroke patients: Results from the EPISODE-PS-COVID study.
   Acad Emerg Med. 2024 Apr 21. doi: 10.1111/acem.14919.
   PubMed         Abstract available
   
   
   Antiviral Res
2. GLITSCHER M, Benz NI, Sabino C, Murra RO, et al
   Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
   Antiviral Res. 2024;226:105891.
   PubMed         Abstract available
   
   
   BMJ
3. 
   Seven days in medicine: 17-23 April 2024.
   BMJ. 2024;385:q924.
   PubMed        
   
4. KANG D
   The ever looming shadow of caregiving.
   BMJ. 2024;385:q726.
   PubMed        
   
5. LAUNER J
   John Launer: Doctors as activists.
   BMJ. 2024;385:q939.
   PubMed        
   
   
   Clin Infect Dis
6. CHUA KP, Fischer MA, Rahman M, Linder JA, et al
   Changes in the Appropriateness of US Outpatient Antibiotic Prescribing After the Coronavirus Disease 2019 Outbreak: An Interrupted Time Series Analysis of 2016-2021 Data.
   Clin Infect Dis. 2024 Apr 22:ciae135. doi: 10.1093.
   PubMed         Abstract available
   
7. VASCONCELOS A, King JD, Nunes-Alves C, Anderson R, et al
   Accelerating Progress Towards the 2030 Neglected Tropical Diseases Targets: How Can Quantitative Modeling Support Programmatic Decisions?
   Clin Infect Dis. 2024;78.
   PubMed         Abstract available
   
   
   Emerg Infect Dis
8. OPE M, Musyoka R, Kiogora J, Wambugu J, et al
   Epidemiology of SARS-CoV-2 in Kakuma Refugee Camp Complex, Kenya, 2020-2021(1).
   Emerg Infect Dis. 2024;30:900-907.
   PubMed         Abstract available
   
9. NOBLE BA, Jiudice SS, Jones JD, Timbrook TT, et al
   Reemergence of Bordetella parapertussis, United States, 2019-2023.
   Emerg Infect Dis. 2024;30:1058-1060.
   PubMed         Abstract available
   
10. YEE R, Carranza D, Kim C, Trinidad JP, et al
    COVID-19 Vaccination Site Accessibility, United States, December 11, 2020-March 29, 2022.
    Emerg Infect Dis. 2024;30:947-955.
    PubMed         Abstract available
    
11. KEHOE AD, Mallhi AK, Barton CR, Martin HM, et al
    SARS-CoV-2 Transmission in Alberta, British Columbia, and Ontario, Canada, January 2020-January 2022.
    Emerg Infect Dis. 2024;30:956-967.
    PubMed         Abstract available
    
12. MOUCHTOURI VA, Kourentis L, Anagnostopoulos L, Koureas M, et al
    Interventional Study of Nonpharmaceutical Measures to Prevent COVID-19 Aboard Cruise Ships.
    Emerg Infect Dis. 2024;30:1030-1033.
    PubMed         Abstract available
    
13. LUSTIG Y, Canetti M, Indenbaum V, Peretz Y, et al
    SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022- and 2023.
    Emerg Infect Dis. 2024;30:1050-1052.
    PubMed         Abstract available
    
14. NGUYENLA XH, Bates TA, Trank-Greene M, Wahedi M, et al
    Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine.
    Emerg Infect Dis. 2024;30.
    PubMed         Abstract available
    
15. DOI A, Ota M, Saito M, Matsuyama S, et al
    Sporadic Occurrence of Ensitrelvir-Resistant SARS-CoV-2, Japan.
    Emerg Infect Dis. 2024;30.
    PubMed         Abstract available
    
    
    Infect Control Hosp Epidemiol
16. TAN C, Chan CK, Ofner M, O’Brien J, et al
    Implementation of point-of-care molecular testing for respiratory viruses in congregate living settings.
    Infect Control Hosp Epidemiol. 2024 Apr 25:1-5. doi: 10.1017/ice.2024.
    PubMed         Abstract available
    
    
    Int J Infect Dis
17. VERGORI A, Cozzi-Lepri A, Tavelli A, Mazzotta V, et al
    SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T cell counts in people living with HIV.
    Int J Infect Dis. 2024 Apr 19:107065. doi: 10.1016/j.ijid.2024.107065.
    PubMed         Abstract available
    
    
    J Infect
18. ZHOU J, Lan L, Ai S, Lin J, et al
    Corrigendum to: “People living with HIV who have poor immune status are a key population for SARS-CoV-2 prevention” Journal of Infection, Volume 88, Issue 3, March 2024, 106122.
    J Infect. 2024 Apr 24:106157. doi: 10.1016/j.jinf.2024.106157.
    PubMed        
    
    
    J Med Virol
19. HSU AY, Lin CJ, Hsia NY, Wang YH, et al
    Reply to comment on “The risk assessment of uveitis after COVID-19 diagnosis by Wu et al. 2024”.
    J Med Virol. 2024;96:e29636.
    PubMed        
    
20. HEWEL C, Schmidt H, Runkel S, Kohnen W, et al
    Nanopore adaptive sampling of a metagenomic sample derived from a human monkeypox case.
    J Med Virol. 2024;96:e29610.
    PubMed         Abstract available
    
21. SONG G, Li R, Cheng MQ
    Safety, immunogenicity, and protective effective of inhaled COVID-19 vaccines: A systematic review and meta-analysis.
    J Med Virol. 2024;96:e29625.
    PubMed         Abstract available
    
    
    J Virol
22. VIOX EG, Bosinger SE, Douek DC, Schreiber G, et al
    Harnessing the power of IFN for therapeutic approaches to COVID-19.
    J Virol. 2024 Apr 23:e0120423. doi: 10.1128/jvi.01204.
    PubMed         Abstract available
    
23. MAO D, Liu S, Phan AT, Renner S, et al
    The TRAF3-DYRK1A-RAD54L2 complex maintains ACE2 expression to promote SARS-CoV-2 infection.
    J Virol. 2024 Apr 23:e0034724. doi: 10.1128/jvi.00347.
    PubMed         Abstract available
    
    
    JAMA
24. HARRIS E
    Antidepressant Prescriptions for Female Teens Surged After Pandemic.
    JAMA. 2024;331:1266.
    PubMed        
    
25. BARNELL EK, Lieberman DA
    Multitarget Stool RNA Testing-Reply.
    JAMA. 2024;331:1419-1420.
    PubMed        
    
26. BAIRD G
    Multitarget Stool RNA Testing.
    JAMA. 2024;331:1418-1419.
    PubMed        
    
27. IMPERIALE TF, Lavin P, Ransohoff DF
    Multitarget Stool RNA Testing.
    JAMA. 2024;331:1418.
    PubMed        
    
28. HARRIS E
    Deaths From Excessive Drinking Rose in the US During Pandemic.
    JAMA. 2024;331:1355.
    PubMed        
    
29. HARRIS E
    Meta-Analysis: “Limited” Benefits to Rapid Viral Tests in EDs.
    JAMA. 2024;331:1355.
    PubMed        
    
30. ALLEN MR, Desai N, Namazi A, Leas E, et al
    Characteristics of X (Formerly Twitter) Community Notes Addressing COVID-19 Vaccine Misinformation.
    JAMA. 2024 Apr 24:e244800. doi: 10.1001/jama.2024.4800.
    PubMed        
    
31. HARRIS E
    WHO Launches Broad Coronavirus Surveillance Network.
    JAMA. 2024 Apr 26. doi: 10.1001/jama.2024.6724.
    PubMed        
    
    
    Lancet
32. DEVI S
    Swedish NGOs are reeling after government cuts.
    Lancet. 2024;403:1527.
    PubMed        
    
33. 
    Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a sys
    Lancet. 2024 Apr 15:S0140-6736(24)00757-8. doi: 10.1016/S0140-6736(24)00757.
    PubMed         Abstract available
    
    
    Lancet Infect Dis
34. JIN SL, Kolis J, Parker J, Proctor DA, et al
    Social histories of public health misinformation and infodemics: case studies of four pandemics.
    Lancet Infect Dis. 2024 Apr 19:S1473-3099(24)00105.
    PubMed         Abstract available
    
35. ZUO W, He D, Liang C, Du S, et al
    The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China.
    Lancet Infect Dis. 2024 Apr 22:S1473-3099(24)00171.
    PubMed         Abstract available
    
36. BUONSENSO D, Tantisira KG
    Long COVID and SARS-CoV-2 persistence: new answers, more questions.
    Lancet Infect Dis. 2024 Apr 22:S1473-3099(24)00216.
    PubMed        
    
    
    Life Sci
37. LI Q, Peng G, Liu H, Wang L, et al
    Molecular mechanisms of secretory autophagy and its potential role in diseases.
    Life Sci. 2024 Apr 23:122653. doi: 10.1016/j.lfs.2024.122653.
    PubMed         Abstract available
    
    
    MMWR Morb Mortal Wkly Rep
38. PANAGIOTAKOPOULOS L, Godfrey M, Moulia DL, Link-Gelles R, et al
    Use of an Additional Updated 2023-2024 COVID-19 Vaccine Dose for Adults Aged >/=65 Years: Recommendations of the Advisory Committee on Immunization Practices – United States, 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:377-381.
    PubMed         Abstract available
    
39. SMITH-JEFFCOAT SE, Mellis AM, Grijalva CG, Talbot HK, et al
    SARS-CoV-2 Viral Shedding and Rapid Antigen Test Performance – Respiratory Virus Transmission Network, November 2022-May 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:365-371.
    PubMed         Abstract available
    
    
    N Engl J Med
40. MOSER CB, Li JZ, Hughes MD
    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
    N Engl J Med. 2024;390:1533-1534.
    PubMed        
    
41. SELVI-SABATER P, de la Rubia Orti JE, Urbieta-Sanz E
    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
    N Engl J Med. 2024;390:1534.
    PubMed        
    
42. WANG Y, Hu H, Cao B
    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19. Reply.
    N Engl J Med. 2024;390:1534-1535.
    PubMed        
    
    
    Nature
43. NOGRADY B
    WHO redefines airborne transmission: what does that mean for future pandemics?
    Nature. 2024 Apr 24. doi: 10.1038/d41586-024-01173.
    PubMed        
    
    
    Radiologia (Engl Ed)
44. PLASENCIA MARTINEZ JM, Garcia Tuells I, Bravo Perez C, Blanco Barrio A, et al
    Target sign in COVID-19, radiological interpretation and diagnostic contribution of digital thoracic tomosynthesis.
    Radiologia (Engl Ed). 2024;66 Suppl 1:S32-S39.
    PubMed         Abstract available
    
45. VALENZUELA C, de la Fuente L, Hernandez S, Olivera MJ, et al
    Persistent pulmonary abnormalities after 18 months of SARS-CoV-2 pneumonia.
    Radiologia (Engl Ed). 2024;66 Suppl 1:S47-S56.
    PubMed         Abstract available
    
    
    Science
46. COHEN J
    Africa steps up battle against mpox outbreaks.
    Science. 2024;384:373-374.
    PubMed         Abstract available

#Coronavirus Disease Research #References (by Amedeo.com, April 20 ’24)

1. ATRAMONT A, Martin GL, Singer M, Tajahmady A, et al
   One-Year Survival and Hospital-free Days in Critical Illness After Viral Pneumonia.
   Am J Respir Crit Care Med. 2024;209:1019-1022.
   PubMed        
   
   
   Ann Intern Med
2. WEITZ HH, Merli GJ
   Annals Consult Guys – COVID-19 and Surgery: A Postpandemic Update.
   Ann Intern Med. 2024;177:eW240001.
   PubMed        
   
3. ALHAMMADI A, Alshawaf R, Chavda S, Ramondino S, et al
   Infectious Diseases: What You May Have Missed in 2023.
   Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0679.
   PubMed         Abstract available
   
4. COSCHI CH, Dodbiba L, Guerry D
   Oncology: What You May Have Missed in 2023.
   Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0520.
   PubMed         Abstract available
   
5. ALHABOBI AAM, Almutairi AMS, Bohemid DASY, Sehgal AR, et al
   Nephrology: What You May Have Missed in 2023.
   Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0605.
   PubMed         Abstract available
   
   
   BMJ
6. COLLINS GS, Moons KGM, Dhiman P, Riley RD, et al
   TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods.
   BMJ. 2024;385:e078378.
   PubMed         Abstract available
   
7. MAHASE E
   Covid-19: Charities question inquiry’s “refusal” to fully examine mental health impact.
   BMJ. 2024;385:q852.
   PubMed        
   
   
   Clin Infect Dis
8. 
   Correction to: Discordant Antibody and T-Cell Responses to the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Coronavirus Disease 2019 Messenger RNA Vaccine Recipients.
   Clin Infect Dis. 2024 Apr 15:ciae165. doi: 10.1093.
   PubMed        
   
   
   Infect Control Hosp Epidemiol
9. BUCHANAN MO, Sickbert-Bennett EE, Selimos A, Dean SM, et al
   Strategies to maintain an N95 respirator supply during a pandemic supply-chain shortage.
   Infect Control Hosp Epidemiol. 2024;45:688-689.
   PubMed        
   
   
   Int J Infect Dis
10. SLURINK IAL, van den Houdt SCM, Mertens G
    Who develops long COVID? Longitudinal pre-pandemic predictors of long COVID and symptom clusters in a representative Dutch population.
    Int J Infect Dis. 2024 Apr 10:107048. doi: 10.1016/j.ijid.2024.107048.
    PubMed         Abstract available
    
11. VERGORI A, Lepri AC, Chiuchiarelli M, Mazzotta V, et al
    Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era.
    Int J Infect Dis. 2024 Apr 11:107042. doi: 10.1016/j.ijid.2024.107042.
    PubMed         Abstract available
    
12. CHEN H, Yu L, Wang L, Zhang J, et al
    Demographic characteristics and risk factors for invasive fungal sinusitis in the context of COVID-19: A systematic review and meta-analysis.
    Int J Infect Dis. 2024 Apr 11:107054. doi: 10.1016/j.ijid.2024.107054.
    PubMed         Abstract available
    
13. LIEW YX, Ho AYL, Wong GC, Chung SJ, et al
    A retrospective study of intravenous pentamidine for PCP prophylaxis in adult patients with hematological malignancies – its utility during respiratory virus pandemics.
    Int J Infect Dis. 2024 Apr 12:107059. doi: 10.1016/j.ijid.2024.107059.
    PubMed         Abstract available
    
14. GRONING R, Walde J, Ahlm C, Forsell MN, et al
    Intravenous immunoglobulin therapy for COVID-19 in immunocompromised patients: a retrospective cohort study.
    Int J Infect Dis. 2024 Apr 12:107046. doi: 10.1016/j.ijid.2024.107046.
    PubMed         Abstract available
    
15. GLASER N, Diexer S, Klee B, Purschke DO, et al
    The contribution of SARS-CoV-2 to the burden of acute respiratory infections in winter season 2022/2023: Results from the DigiHero study.
    Int J Infect Dis. 2024 Apr 15:107057. doi: 10.1016/j.ijid.2024.107057.
    PubMed         Abstract available
    
16. RICCIO MD, Caini S, Bonaccorsi G, Lorini C, et al
    Global analysis of respiratory viral circulation and timing of epidemics in the pre-COVID-19 and COVID-19 pandemic eras, based on data from the Global Influenza Surveillance and Response System (GISRS).
    Int J Infect Dis. 2024 Apr 16:107052. doi: 10.1016/j.ijid.2024.107052.
    PubMed         Abstract available
    
17. GRIFFITHS M, Hatabah D, Sullivan P, Mantus G, et al
    Incidence of SARS-CoV-2 Seropositivity in Pediatric Healthcare Workers Prior to Widespread Vaccination: A Five-month Longitudinal Cohort Study.
    Int J Infect Dis. 2024 Apr 17:107064. doi: 10.1016/j.ijid.2024.107064.
    PubMed         Abstract available
    
    
    J Infect
18. CHUN JY, Jeong SJ, Kim S, Choi S, et al
    Performance of the Galactomannan Test for the Diagnosis of Invasive Pulmonary Aspergillosis using Non-invasive Proximal Airway Samples.
    J Infect. 2024 Apr 17:106159. doi: 10.1016/j.jinf.2024.106159.
    PubMed         Abstract available
    
    
    J Med Virol
19. MENG H, Wang Y, Zhai Y, Luo W, et al
    Unveiling the micronutrient-immunity puzzle in inactivated COVID-19 vaccination: A comprehensive analysis of circulating micronutrient levels and humoral responses in healthy adults.
    J Med Virol. 2024;96:e29611.
    PubMed         Abstract available
    
20. MAHLA RS, Dustin LB
    COVID-19 vaccination and autoimmunity: Do we need more evidence?
    J Med Virol. 2024;96:e29623.
    PubMed        
    
21. WEI M, Li S, Lu X, Hu K, et al
    Changing respiratory pathogens infection patterns after COVID-19 pandemic in Shanghai, China.
    J Med Virol. 2024;96:e29616.
    PubMed         Abstract available
    
22. OKITSU S, Khamrin P, Hikita T, Onda Y, et al
    Remarkable increase in the detection and molecular characterization of adenovirus F41 in children with acute gastroenteritis in Japan, 2017-2023.
    J Med Virol. 2024;96:e29615.
    PubMed         Abstract available
    
23. MATUSALI G, Vergori A, Cimini E, Mariotti D, et al
    Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
    J Med Virol. 2024;96:e29598.
    PubMed         Abstract available
    
24. CHEN IW, Weng HL, Lai YC, Hung KC, et al
    Incidence of fatigue 2 years after SARS-CoV-2 infection: An updated meta-analysis and subgroup analysis.
    J Med Virol. 2024;96:e29619.
    PubMed        
    
25. DESTREMAU M, Chaussade H, Hemar V, Beguet M, et al
    Convalescent plasma transfusion for immunocompromised viremic patients with COVID-19: A retrospective multicenter study.
    J Med Virol. 2024;96:e29603.
    PubMed         Abstract available
    
26. SUN Q, Gao J, An R, Wang M, et al
    Probing molecular pathways: Illuminating the connection between COVID-19 and Alzheimer’s disease through the endocannabinoid system dynamics.
    J Med Virol. 2024;96:e29590.
    PubMed         Abstract available
    
    
    J Travel Med
27. WARDLE J, Bhatia S, Cori A, Nouvellet P, et al
    Temporal variations in international air travel: implications for modelling the spread of infectious diseases.
    J Travel Med. 2024 Mar 17:taae062. doi: 10.1093.
    PubMed         Abstract available
    
    
    J Virol
28. HAN Y, Yuan Z, Yi Z
    Identification of a membrane-associated element (MAE) in the C-terminal region of SARS-CoV-2 nsp6 that is essential for viral replication.
    J Virol. 2024 Apr 19:e0034924. doi: 10.1128/jvi.00349.
    PubMed         Abstract available
    
29. PEREZ DR
    A devastating blow: personal reflections on Argentina’s scientific decline.
    J Virol. 2024 Apr 16:e0054924. doi: 10.1128/jvi.00549.
    PubMed         Abstract available
    
30. EBRIGHT RH, MacIntyre R, Dudley JP, Butler CD, et al
    Implementing governmental oversight of enhanced potential pandemic pathogen research.
    J Virol. 2024;98:e0023724.
    PubMed        
    
31. TAKADA K, Orba Y, Kida Y, Wu J, et al
    Genes involved in the limited spread of SARS-CoV-2 in the lower respiratory airways of hamsters may be associated with adaptive evolution.
    J Virol. 2024 Apr 16:e0178423. doi: 10.1128/jvi.01784.
    PubMed         Abstract available
    
32. WANG X, Qiu W, Hu G, Diao X, et al
    NS7a of SADS-CoV promotes viral infection via inducing apoptosis to suppress type III interferon production.
    J Virol. 2024 Apr 16:e0031724. doi: 10.1128/jvi.00317.
    PubMed         Abstract available
    
33. ISHIMARU H, Nishimura M, Shigematsu H, Marini MI, et al
    Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
    J Virol. 2024 Apr 16:e0041624. doi: 10.1128/jvi.00416.
    PubMed         Abstract available
    
    
    Lancet Infect Dis
34. 
    Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet Infect Dis. 2024 Apr 16:S1473-3099(24)00158.
    PubMed         Abstract available
    
35. 
    Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.
    Lancet Infect Dis. 2024 Apr 15:S1473-3099(24)00176.
    PubMed         Abstract available
    
    
    MMWR Morb Mortal Wkly Rep
36. FRANKLIN D, Barbre K, Rowe TA, Reses HE, et al
    COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19-Associated Hospitalization Among Residents in Nursing Homes – National Healthcare Safety Network, United States, October 2023-February 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:339-344.
    PubMed         Abstract available
    
37. ZAMBRANO LD, Newhams MM, Simeone RM, Payne AB, et al
    Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents – United States, 2021-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:330-338.
    PubMed         Abstract available
    
    
    Nature
38. DOLGIN E
    mRNA drug offers hope for treating a devastating childhood disease.
    Nature. 2024;628:248.
    PubMed        
    
39. KOZLOV M
    US COVID-origins hearing puts scientific journals in the hot seat.
    Nature. 2024 Apr 16. doi: 10.1038/d41586-024-01129.
    PubMed        
    
40. LADYZHETS B
    What toilets can reveal about COVID, cancer and other health threats.
    Nature. 2024;628:492-494.
    PubMed        
    
    
    Science
41. COUZIN-FRANKEL J
    Lessons in persistence.
    Science. 2024;384:150-154.
    PubMed         Abstract available

#Coronavirus Disease Research #References (by Amedeo.com, April 13 ’24)

1. RADCLIFFE C, Kotton CN
   En Garde or On Board? Travel Medicine for Immunocompromised Patients in the COVID-19 Era.
   Ann Intern Med. 2024 Apr 9. doi: 10.7326/M24-0256.
   PubMed        
   
   
   Antiviral Res
2. TOLKSDORF B, Heinze J, Niemeyer D, Rohrs V, et al
   Development of a highly stable, active small interfering RNA with broad activity against SARS-CoV viruses.
   Antiviral Res. 2024 Apr 8:105879. doi: 10.1016/j.antiviral.2024.105879.
   PubMed         Abstract available
   
   
   Clin Infect Dis
3. MCAULEY JB
   COVID at the Whiteriver Indian Hospital.
   Clin Infect Dis. 2024;78:815-817.
   PubMed        
   
4. ZAWADZKA S
   Family Ties and COVID Lies.
   Clin Infect Dis. 2024;78:813-814.
   PubMed        
   
5. TIPPETT A, Ess G, Hussaini L, Reese O, et al
   Influenza Vaccine Effectiveness Pre-pandemic among Adults Hospitalized with Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, and Older Adults.
   Clin Infect Dis. 2023 Nov 8:ciad679. doi: 10.1093.
   PubMed         Abstract available
   
6. VAN DER VAART TW, Prins JM, Goorhuis A, Lemkes BA, et al
   The utility of risk factors to define complicated Staphylococcus aureus bacteremia in a setting with low MRSA prevalence.
   Clin Infect Dis. 2023 Dec 29:ciad784. doi: 10.1093.
   PubMed         Abstract available
   
7. SHERMAN A, Tuan J, Cantos VD, Adeyiga O, et al
   COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials.
   Clin Infect Dis. 2024 Apr 10:ciae192. doi: 10.1093.
   PubMed         Abstract available
   
8. PETROS BA, Milliren CE, Sabeti PC, Ozonoff A, et al
   Increased Pediatric Respiratory Syncytial Virus Case Counts Following the Emergence of Severe Acute Respiratory Syndrome Coronavirus 2 Can Be Attributed to Changes in Testing.
   Clin Infect Dis. 2024 Apr 11:ciae140. doi: 10.1093.
   PubMed         Abstract available
   
9. RUBIS AB, Cole M, Tondella ML, Pawloski LC, et al
   Assessing the Impact of the 2020 Council of State and Territorial Epidemiologists Case Definition for Pertussis on Reported Pertussis Cases.
   Clin Infect Dis. 2024 Apr 12:ciae207. doi: 10.1093.
   PubMed         Abstract available
   
   
   Int J Infect Dis
10. MARKUSSEN DL, Kommedal O, Knoop ST, Ebbesen MH, et al
    Microbial aetiology of community-acquired pneumonia in hospitalized adults: a prospective study utilising comprehensive molecular testing.
    Int J Infect Dis. 2024 Apr 4:107019. doi: 10.1016/j.ijid.2024.107019.
    PubMed         Abstract available
    
11. TAMURA K, Shimbashi R, Kasamatsu A, Chang B, et al
    Unveiling the role of preceding seasonal influenza in the development of bacteremic pneumococcal pneumonia in older adults before the COVID-19 pandemic in Japan.
    Int J Infect Dis. 2024 Apr 5:107024. doi: 10.1016/j.ijid.2024.107024.
    PubMed         Abstract available
    
12. FAVRESSE J, Gillot C, Cabo J, David C, et al
    Neutralizing antibody response to XBB.1.5, BA.2.86, FL.1.5.1 and JN.1 six months after the BNT162b2 bivalent booster.
    Int J Infect Dis. 2024 Apr 5:107028. doi: 10.1016/j.ijid.2024.107028.
    PubMed         Abstract available
    
13. YU J, Zhang K, Chen T, Lin R, et al
    Temporal patterns of organ dysfunction in COVID-19 patients hospitalized in the intensive care unit: A group-based multitrajectory modelling analysis.
    Int J Infect Dis. 2024 Apr 9:107045. doi: 10.1016/j.ijid.2024.107045.
    PubMed         Abstract available
    
    
    J Infect
14. PINANA M, Gonzalez-Sanchez A, Andres C, Vila J, et al
    Genomic evolution of human respiratory syncytial virus during a decade (2013-2023): bridging the path to monoclonal antibody surveillance.
    J Infect. 2024 Apr 6:106153. doi: 10.1016/j.jinf.2024.106153.
    PubMed         Abstract available
    
    
    J Med Virol
15. ARUNAN B, Talukdar D, Swain S, Varadarajan A, et al
    Metagenomic insights into fungal community composition of the nasopharyngeal region of COVID-19 associated mucormycosis patients from India.
    J Med Virol. 2024;96:e29601.
    PubMed         Abstract available
    
16. LI Y, Yu J, Wang Y, Yi J, et al
    Cocirculation and coinfection of multiple respiratory viruses during autumn and winter seasons of 2023 in Beijing, China: A retrospective study.
    J Med Virol. 2024;96:e29602.
    PubMed         Abstract available
    
17. PARK D, Kim SM, Jang H, Kim K, et al
    Differential beta-coronavirus infection dynamics in human bronchial epithelial organoids.
    J Med Virol. 2024;96:e29600.
    PubMed         Abstract available
    
18. SVIERCZ F, Jarmoluk P, Godoy Coto J, Cevallos C, et al
    The abortive SARS-CoV-2 infection of osteoclast precursors promotes their differentiation into osteoclasts.
    J Med Virol. 2024;96:e29597.
    PubMed         Abstract available
    
19. RAI P, Marano JM, Kang L, Coutermarsh-Ott S, et al
    Obesity fosters severe disease outcomes in a mouse model of coronavirus infection associated with transcriptomic abnormalities.
    J Med Virol. 2024;96:e29587.
    PubMed         Abstract available
    
20. KURYLOWICZ A, Babicki M, Wasowski M, Jankowski P, et al
    Triglicerydes/high-density lipoprotein ratio as a risk factor of post-Covid-19 sinus tachycardia: A retrospective study.
    J Med Virol. 2024;96:e29586.
    PubMed         Abstract available
    
21. YE G, Tang Y, Yang Q, Zhang C, et al
    A peptide derived from SARS-CoV-2 nucleocapsid protein with broad-spectrum anti-coronavirus activity.
    J Med Virol. 2024;96:e29492.
    PubMed        
    
    
    J Travel Med
22. CHEMAITELLY H, Coyle P, Kacem MAB, Ayoub HH, et al
    Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant.
    J Travel Med. 2024 Apr 9:taae053. doi: 10.1093.
    PubMed         Abstract available
    
    
    J Virol
23. BOON ACM, Bricker TL, Fritch EJ, Leist SR, et al
    Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19.
    J Virol. 2024 Apr 9:e0190323. doi: 10.1128/jvi.01903.
    PubMed         Abstract available
    
24. ZHOU J, Sun P, Wang Y, Qiu R, et al
    Deep profiling of potential substrate atlas of porcine epidemic diarrhea virus 3C-like protease.
    J Virol. 2024 Apr 9:e0025324. doi: 10.1128/jvi.00253.
    PubMed         Abstract available
    
25. YANG R, Han P, Han P, Li D, et al
    Molecular basis of hippopotamus ACE2 binding to SARS-CoV-2.
    J Virol. 2024 Apr 9:e0045124. doi: 10.1128/jvi.00451.
    PubMed         Abstract available
    
    
    JAMA
26. HARRIS E
    COVID-19 Vaccination Linked With Lower Risk of Cardiac Problems.
    JAMA. 2024 Apr 12. doi: 10.1001/jama.2024.5152.
    PubMed        
    
27. DAWOOD FS, Payne AB, McMorrow ML
    Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus.
    JAMA. 2024 Apr 11. doi: 10.1001/jama.2024.5859.
    PubMed        
    
    
    Lancet
28. 
    Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024 Apr 3:S0140-6736(24)00367-2. doi: 10.1016/S0140-6736(24)00367.
    PubMed         Abstract available
    
29. GU X, Huang L, Zhang H, Cao B, et al
    Post-COVID-19 condition symptoms 6-12 months after hospitalisation in Wuhan – Authors’ reply.
    Lancet. 2024;403:1336-1337.
    PubMed        
    
30. SORAAS A, Brunvoll SH, Nygaard AB, Dahl JA, et al
    Post-COVID-19 condition symptoms 6-12 months after hospitalisation in Wuhan.
    Lancet. 2024;403:1336.
    PubMed        
    
31. HASHIM Z, Nath A, Tripathy NK
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1337-1338.
    PubMed        
    
32. MCEVOY N, Lowry J, O’Dowd A, Curley GF, et al
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1337.
    PubMed        
    
33. HSU NC, Tokuda Y
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1338.
    PubMed        
    
34. NARASARAJU T, Ravi Y, Jonsson CB, Chow VTK, et al
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1338-1339.
    PubMed        
    
35. BHUSAL S, Adhikari S
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1339.
    PubMed        
    
36. PETO L, Basnyat B, Horby P
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial – Authors’ reply.
    Lancet. 2024;403:1339-1340.
    PubMed        
    
37. ZUMLA A, Peiris M, Memish ZA, Perlman S, et al
    Anticipating a MERS-like coronavirus as a potential pandemic threat.
    Lancet. 2024 Apr 8:S0140-6736(24)00641-X. doi: 10.1016/S0140-6736(24)00641.
    PubMed        
    
    
    Lancet Infect Dis
38. PELUSO MJ, Swank ZN, Goldberg SA, Lu S, et al
    Plasma-based antigen persistence in the post-acute phase of COVID-19.
    Lancet Infect Dis. 2024 Apr 8:S1473-3099(24)00211.
    PubMed        
    
    
    MMWR Morb Mortal Wkly Rep
39. DOSHI RH, Nsasiirwe S, Dahlke M, Atagbaza A, et al
    COVID-19 Vaccination Coverage – World Health Organization African Region, 2021-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:307-311.
    PubMed         Abstract available
    
40. LIKO J, Cieslak PR
    Assessment of Risk for Sudden Cardiac Death Among Adolescents and Young Adults After Receipt of COVID-19 Vaccine – Oregon, June 2021-December 2022.
    MMWR Morb Mortal Wkly Rep. 2024;73:317-320.
    PubMed         Abstract available
    
    
    N Engl J Med
41. HAMMOND J, Fountaine RJ, Yunis C, Fleishaker D, et al
    Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
    N Engl J Med. 2024;390:1186-1195.
    PubMed         Abstract available
    
42. GANDHI RT, Hirsch M
    Treating Acute Covid-19 – Final Chapters Still Unwritten.
    N Engl J Med. 2024;390:1234-1236.
    PubMed        
    
    
    Zhonghua Jie He He Hu Xi Za Zhi
43. SUN ZZ, Sun GF, Zhuang R, Zhu LQ, et al
    [Best evidence summary for awake prone positioning in treating hypoxemic due to COVID-19 infection].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:313-318.
    PubMed         Abstract available

#Coronavirus Disease Research #References (by Amedeo.com, April 6 ’24)

1. HOFFMANN JA, Carter CP, Olsen CS, Ashby D, et al
   Pediatric mental health emergency department visits from 2017 to 2022: A multicenter study.
   Acad Emerg Med. 2024 Apr 2. doi: 10.1111/acem.14910.
   PubMed         Abstract available
   
   
   Am J Obstet Gynecol
2. GABBY LC, Jones CK, McIntyre BB, Manalo Z, et al
   Chronic Villitis as a Distinctive Feature of Placental Injury in Maternal SARS-CoV-2 Infection.
   Am J Obstet Gynecol. 2024 Apr 3:S0002-9378(24)00480.
   PubMed         Abstract available
   
   
   Am J Respir Crit Care Med
3. CURLEY GF, O’Kane CM, McAuley DF, Matthay MA, et al
   Cell-based Therapies for Acute Respiratory Distress Syndrome: Where Are We Now?
   Am J Respir Crit Care Med. 2024;209:789-797.
   PubMed         Abstract available
   
   
   Ann Intern Med
4. GOTUR D, Mylonakis E
   In adults with post-COVID-19 conditions, a synbiotic preparation, SIM01, alleviated some symptoms at 6 mo.
   Ann Intern Med. 2024 Apr 2. doi: 10.7326/J24-0018.
   PubMed         Abstract available
   
   
   Antiviral Res
5. SINIAVIN AE, Gushchin VA, Shastina NS, Darnotuk ES, et al
   New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
   Antiviral Res. 2024 Mar 28:105871. doi: 10.1016/j.antiviral.2024.105871.
   PubMed         Abstract available
   
6. KHATUA K, Alugubelli YR, Yang KS, Vulupala VR, et al
   Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
   Antiviral Res. 2024;225:105874.
   PubMed         Abstract available
   
   
   BMJ
7. FONG KJ, Summers C, Cook TM
   NHS hospital capacity during covid-19: overstretched staff, space, systems, and stuff.
   BMJ. 2024;385:e075613.
   PubMed        
   
   
   Clin Infect Dis
8. TERZIC V, Miantezila Basilua J, Billard N, de Gastines L, et al
   Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.
   Clin Infect Dis. 2024 Mar 29:ciae170. doi: 10.1093.
   PubMed         Abstract available
   
9. BIERE-RAFI S, Janssen K, Jurgens E, Kooij S, et al
   Is Cognitive Behavioural Therapy Effective for Post-COVID Fatigue?
   Clin Infect Dis. 2023;77:1074-1075.
   PubMed        
   
10. GOTTLIEB RL, Kalil AC
    True DisCoVeRy of COVID-19 Disease Burden Versus Speculated Antiviral Cardiovascular Risk Requires a Control Group.
    Clin Infect Dis. 2024 Mar 29:ciae172. doi: 10.1093.
    PubMed        
    
    
    Emerg Infect Dis
11. TUNSTALL AM, O’Brien SC, Monaghan DM, Burakoff A, et al
    Lessons Learned from Cross-Systems Approach to COVID-19 Pandemic Response in Juvenile Justice System, Colorado, USA.
    Emerg Infect Dis. 2024;30:S13-S16.
    PubMed         Abstract available
    
12. WADDELL C, Meehan A, Schoonveld M, Kaplan Z, et al
    Lessons Learned from COVID-19 Response in Correctional and Detention Facilities.
    Emerg Infect Dis. 2024;30:S5-S12.
    PubMed         Abstract available
    
13. GURREY SO, Strick LB, Dov LK, Miller JS, et al
    Lessons Learned from Public Health and State Prison Collaborations during COVID-19 Pandemic and Multifacility Tuberculosis Outbreak, Washington, USA.
    Emerg Infect Dis. 2024;30:S17-S20.
    PubMed         Abstract available
    
14. HAGAN LM, Mosites E, Hughes-Baker L, Butler J, et al
    Carceral Health is Public Health.
    Emerg Infect Dis. 2024;30:S1-S4.
    PubMed        
    
15. SABER LB, Kennedy SS, Yang Y, Moore KN, et al
    Correlation of SARS-CoV-2 in Wastewater and Individual Testing Results in a Jail, Atlanta, Georgia, USA.
    Emerg Infect Dis. 2024;30:S21-S27.
    PubMed         Abstract available
    
16. PORTER LJ, Rapheal E, Huebsch R, Bastian T, et al
    Development and Evaluation of Surveillance System for Identifying Jail-Associated COVID-19 Cases in Minnesota, USA, 2022.
    Emerg Infect Dis. 2024;30:S28-S35.
    PubMed         Abstract available
    
17. KENDIG NE, Bur S, Zaslavsky J
    Infection Prevention and Control in Correctional Settings.
    Emerg Infect Dis. 2024;30:S88-S93.
    PubMed         Abstract available
    
    
    Infect Control Hosp Epidemiol
18. LEIS JA, Chan CK, Tan C, Callahan J, et al
    Predictors of SARS-CoV-2 transmission in congregate living settings: a multicenter prospective study.
    Infect Control Hosp Epidemiol. 2024 Apr 2:1-6. doi: 10.1017/ice.2024.
    PubMed         Abstract available
    
    
    Int J Infect Dis
19. CORRECHER-MARTINEZ E, Lopez-Lacort M, Munoz-Quiles C, Diez-Domingo J, et al
    Risk of herpes zoster in adults with SARS-CoV-2 infection in Spain: a population-based, retrospective cohort study.
    Int J Infect Dis. 2024 Apr 2:107037. doi: 10.1016/j.ijid.2024.107037.
    PubMed         Abstract available
    
20. SALVADORI N, Jourdain G, Krittayaphong R, Siripongboonsitti T, et al
    Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: a randomized controlled trial in Thailand.
    Int J Infect Dis. 2024 Mar 30:107021. doi: 10.1016/j.ijid.2024.107021.
    PubMed         Abstract available
    
    
    J Infect
21. COLSON P, Chaudet H, Delerce J, Pontarotti P, et al
    Role of SARS-CoV-2 mutations in the evolution of the COVID-19 pandemic.
    J Infect. 2024 Apr 1:106150. doi: 10.1016/j.jinf.2024.106150.
    PubMed         Abstract available
    
22. NG M, S D, L W, R B, et al
    Paediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology.
    J Infect. 2024 Mar 27:106145. doi: 10.1016/j.jinf.2024.106145.
    PubMed         Abstract available
    
    
    J Med Virol
23. HUNG KC, Yu TS, Wang KF, Chen IW, et al
    Influenza vaccination on SARS-CoV-2 infection risk: A subgroup analysis on geographic factor.
    J Med Virol. 2024;96:e29576.
    PubMed        
    
24. FAN Y, Huang S, Wu D, Chu M, et al
    Immune features revealed by single-cell RNA and single-cell TCR/BCR sequencing in patients with rheumatoid arthritis receiving COVID-19 booster vaccination.
    J Med Virol. 2024;96:e29573.
    PubMed         Abstract available
    
25. MELE D, Ottolini S, Lombardi A, Conteianni D, et al
    Long-term dynamics of natural killer cells in response to SARS-CoV-2 vaccination: Persistently enhanced activity postvaccination.
    J Med Virol. 2024;96:e29585.
    PubMed         Abstract available
    
26. YANG H, Guan L, Yang T, Ma H, et al
    Two- and 3-year outcomes in convalescent individuals with COVID-19: A prospective cohort study.
    J Med Virol. 2024;96:e29566.
    PubMed         Abstract available
    
27. GANDIKOTA C, Vaddadi K, Sivasami P, Huang C, et al
    The use of human iPSC-derived alveolar organoids to explore SARS-CoV-2 variant infections and host responses.
    J Med Virol. 2024;96:e29579.
    PubMed         Abstract available
    
28. WOO HG, Kim HJ, Park J, Lee J, et al
    Global burden of vaccine-associated multiple sclerosis, 1967-2022: A comprehensive analysis of the international pharmacovigilance database.
    J Med Virol. 2024;96:e29591.
    PubMed         Abstract available
    
29. HE S, Liu SQ, Teng XY, He JY, et al
    Comparative single-cell RNA sequencing analysis of immune response to inactivated vaccine and natural SARS-CoV-2 infection.
    J Med Virol. 2024;96:e29577.
    PubMed         Abstract available
    
30. GUNGOR K, Bukavaz S, Ekuklu G
    Measles outbreak in the adult age group: Clinical, laboratory, and epidemiological features of the 11 patients admitted to the hospital.
    J Med Virol. 2024;96:e29583.
    PubMed         Abstract available
    
    
    J Virol
31. ZHU Z, Han Y, Gong M, Sun B, et al
    Establishment of replication-competent vesicular stomatitis virus recapitulating SADS-CoV entry.
    J Virol. 2024 Apr 1:e0195723. doi: 10.1128/jvi.01957.
    PubMed         Abstract available
    
32. NAMBULLI S, Escriou N, Rennick LJ, Demers MJ, et al
    A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
    J Virol. 2024 Apr 2:e0176223. doi: 10.1128/jvi.01762.
    PubMed         Abstract available
    
33. BRUNET J, Choucha Z, Gransagne M, Tabbal H, et al
    A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
    J Virol. 2024 Apr 2:e0169323. doi: 10.1128/jvi.01693.
    PubMed         Abstract available
    
34. XIAO X, Fu Y, You W, Huang C, et al
    Inhibition of the RLR signaling pathway by SARS-CoV-2 ORF7b is mediated by MAVS and abrogated by ORF7b-homologous interfering peptide.
    J Virol. 2024 Apr 4:e0157323. doi: 10.1128/jvi.01573.
    PubMed         Abstract available
    
    
    JAMA
35. ANDERER S
    Study: 1 of Every 9 US Cancer Cases Missed During 2020 Pandemic.
    JAMA. 2024;331:1082.
    PubMed        
    
36. GUSSIN GM, McKinnell JA, Singh RD, Miller LG, et al
    Reducing Hospitalizations and Multidrug-Resistant Organisms via Regional Decolonization in Hospitals and Nursing Homes.
    JAMA. 2024 Apr 1:e242759. doi: 10.1001/jama.2024.2759.
    PubMed         Abstract available
    
    
    Lancet
37. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    PubMed         Abstract available
    
    
    Lancet Infect Dis
38. LARIVIERE Y, Matuvanga TZ, Osang’ir BI, Milolo S, et al
    Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised
    Lancet Infect Dis. 2024 Mar 26:S1473-3099(24)00058.
    PubMed         Abstract available
    
    
    MMWR Morb Mortal Wkly Rep
39. EL KALACH R, Jones-Jack N, Elam MA, Olorukooba A, et al
    Federal Retail Pharmacy Program Contributions to Bivalent mRNA COVID-19 Vaccinations Across Sociodemographic Characteristics – United States, September 1, 2022-September 30, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:286-290.
    PubMed         Abstract available
    
    
    Nature
40. BARNES CO, Jette CA, Abernathy ME, Dam KA, et al
    Author Correction: SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.
    Nature. 2024 Apr 2. doi: 10.1038/s41586-024-07344.
    PubMed        
    
41. FAIRBANK R
    Long COVID still has no cure – so these patients are turning to research.
    Nature. 2024;628:26-28.
    PubMed        
    
42. KANG Y, Hepojoki J, Maldonado RS, Mito T, et al
    Ancestral allele of DNA polymerase gamma modifies antiviral tolerance.
    Nature. 2024 Apr 3. doi: 10.1038/s41586-024-07260.
    PubMed         Abstract available
    
    
    Radiol Imaging Cancer
43. SPRAGUE BL, Nowak SA, Ahern TP, Herschorn SD, et al
    Long-term Mammography Screening Trends and Predictors of Return to Screening after the COVID-19 Pandemic: Results from a Statewide Registry.
    Radiol Imaging Cancer. 2024;6:e230161.
    PubMed         Abstract available

#Coronavirus Disease Research #References (by Amedeo.com, March 30 ’24)

1. LI X, Ding G, Li S, Liu C, et al
   Proteomic characteristics of the treatment trajectory of patients with COVID-19.
   Arch Virol. 2024;169:84.
   PubMed         Abstract available
   
   
   Biochem Biophys Res Commun
2. HE K, Ye Y, Liu S, Yuan P, et al
   Polylevodopa nanoplatform for lateral flow immunochromatography assay of SARS-CoV-2 and influenza A virus.
   Biochem Biophys Res Commun. 2024;709:149821.
   PubMed         Abstract available
   
   
   BMC Pediatr
3. TANG CM, Kuo CY, Yen CW, Lin JJ, et al
   Predicting factors for acute encephalopathy in febrile seizure children with SARS-CoV-2 omicron variant: a retrospective study.
   BMC Pediatr. 2024;24:211.
   PubMed         Abstract available
   
   
   BMJ
4. MAHASE E
   Covid-19: Pfizer vaccine to be available privately at pharmacy chain Boots from April.
   BMJ. 2024;384:q762.
   PubMed        
   
5. SHEPHERD A
   Covid remembered in NHS portraits.
   BMJ. 2024;384:q741.
   PubMed        
   
   
   J Virol
6. BRICKER TL, Joshi A, Soudani N, Scheaffer SM, et al
   Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
   J Virol. 2024 Feb 2:e0120623. doi: 10.1128/jvi.01206.
   PubMed         Abstract available
   
   
   JAMA
7. HARRIS E
   Better Outcomes When Kidney Damage Is From COVID-19.
   JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1574.
   PubMed        
   
8. HARRIS E
   HPV Vaccination Rates Stagnated During COVID-19 Pandemic.
   JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1569.
   PubMed        
   
9. HARRIS E
   CDC Tracking BA.2.87.1, New Omicron Subvariant With Potential to Evade Immunity.
   JAMA. 2024;331:907.
   PubMed        
   
10. ANDERSSON NW, Thiesson EM, Hviid A
    Adverse Events After XBB.1.5-Containing COVID-19 mRNA Vaccines.
    JAMA. 2024 Feb 26:e241036. doi: 10.1001/jama.2024.1036.
    PubMed        
    
    
    Lancet
11. PARHIZ H, Atochina-Vasserman EN, Weissman D
    mRNA-based therapeutics: looking beyond COVID-19 vaccines.
    Lancet. 2024 Mar 7:S0140-6736(23)02444-3. doi: 10.1016/S0140-6736(23)02444.
    PubMed         Abstract available
    
12. SHAWE-TAYLOR M, Greenwood D, Hobbs A, Dowgier G, et al
    Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.
    Lancet. 2024 Mar 11:S0140-6736(24)00316-7. doi: 10.1016/S0140-6736(24)00316.
    PubMed        
    
13. SZANYI J, Howe S, Blakely T
    The importance of reporting accurate estimates of long COVID prevalence.
    Lancet. 2024;403:1136-1137.
    PubMed        
    
    
    MMWR Morb Mortal Wkly Rep
14. WILLIAMS SL, Smith DJ, Benedict K, Ahlers JR, et al
    Surveillance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis During the COVID-19 Pandemic – United States, 2019-2021.
    MMWR Morb Mortal Wkly Rep. 2024;73:239-244.
    PubMed         Abstract available
    
    
    PLoS Comput Biol
15. HASSE T, Mantei E, Shahoei R, Pawnikar S, et al
    Mechanistic insights into ligand dissociation from the SARS-CoV-2 spike glycoprotein.
    PLoS Comput Biol. 2024;20:e1011955.
    PubMed         Abstract available
    
    
    PLoS One
16. SCHUMACHER A, Micheli L
    Anticipated scarcity and stockpiling during the COVID-19 pandemic: The role of perceived threat, childhood SES and materialism.
    PLoS One. 2024;19:e0294497.
    PubMed         Abstract available
    
17. ABUGATTAS-NUNEZ DEL PRADO J, Quintana Reyes A, Leon J, Blume La Torre J, et al
    Clinical validation of RCSMS: A rapid and sensitive CRISPR-Cas12a test for the molecular detection of SARS-CoV-2 from saliva.
    PLoS One. 2024;19:e0290466.
    PubMed         Abstract available
    
18. TIRUNEH GT, Fesseha N, Emaway D, Betemariam W, et al
    Effect of community-based newborn care implementation strategies on access to and effective coverage of possible serious bacterial infection (PSBI) treatment for sick young infants during COVID-19 pandemic.
    PLoS One. 2024;19:e0300880.
    PubMed         Abstract available
    
19. AHMAD T, Ibrahim M, Naz O, Abdullah M, et al
    Optimizing immunization services: A Data Envelopment Analysis (DEA) of child immunization facilities in Pakistan.
    PLoS One. 2024;19:e0298308.
    PubMed         Abstract available
    
20. GHEIDARI D, Mehrdad M, Bayat M
    Synthesis, molecular docking analysis, molecular dynamic simulation, ADMET, DFT, and drug likeness studies: Novel Indeno[1,2-b]pyrrol-4(1H)-one as SARS-CoV-2 main protease inhibitors.
    PLoS One. 2024;19:e0299301.
    PubMed         Abstract available
    
21. WAN PUTEH SE, Aazmi MS, Aziz MN, Kamarudin N’, et al
    Cross-sectional study of influenza trends and costs in Malaysia between 2016 and 2018.
    PLoS One. 2024;19:e0301068.
    PubMed         Abstract available
    
22. TAILLANDIER P, Chapuis K, Gaudou B, Brugiere A, et al
    COMOKIT v2: A multi-scale approach to modeling and simulating epidemic control policies.
    PLoS One. 2024;19:e0299626.
    PubMed         Abstract available
    
23. THIEULENT CJ, Carossino M, Peak L, Wolfson W, et al
    Development and validation of multiplex one-step qPCR/RT-qPCR assays for simultaneous detection of SARS-CoV-2 and pathogens associated with feline respiratory disease complex.
    PLoS One. 2024;19:e0297796.
    PubMed         Abstract available
    
24. ZHAO L, Ferraro P, Shorten R
    A smart mask to enforce social contracts based on IOTA Tangle.
    PLoS One. 2024;19:e0292850.
    PubMed         Abstract available
    
25. TOWNSLEY H, Gahir J, Russell TW, Greenwood D, et al
    COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.
    PLoS One. 2024;19:e0294897.
    PubMed         Abstract available
    
26. ADAMCZYK G
    Pathological buying on the rise? Compensative and compulsive buying in Poland in the pre- and (Post-)pandemic times.
    PLoS One. 2024;19:e0298856.
    PubMed         Abstract available
    
27. GUERRERIO AL, Mateja A, MacCarrick G, Fintzi J, et al
    Web-based survey investigating cardiovascular complications in hypermobile Ehlers-Danlos syndrome after COVID-19 infection and vaccination.
    PLoS One. 2024;19:e0298272.
    PubMed         Abstract available
    
28. GEORGE JF
    Discovering why people believe disinformation about healthcare.
    PLoS One. 2024;19:e0300497.
    PubMed         Abstract available
    
29. ZHOU R, Johnson KE, Rousseau JF, Rathouz PJ, et al
    Comparative effectiveness of dexamethasone in treatment of hospitalized COVID-19 patients in the United States during the first year of the pandemic: Findings from the National COVID Cohort Collaborative (N3C) data repository.
    PLoS One. 2024;19:e0294892.
    PubMed         Abstract available
    
30. NAGASAWA S, Hirata Y, Miyamoto S, Ozono S, et al
    Changes in SARS-CoV-2 viral load and titers over time in SARS-CoV-2-infected human corpses.
    PLoS One. 2024;19:e0287068.
    PubMed         Abstract available
    
31. DIMNJAKOVIC J, Buble T, Ivanko P, Poljicanin T, et al
    Association of anti-diabetic drugs and covid-19 outcomes in patients with diabetes mellitus type 2 and chronic kidney disease: Nationwide registry analysis.
    PLoS One. 2024;19:e0301056.
    PubMed         Abstract available
    
32. KOMORI A, Mori H, Xie W, Valenti S, et al
    Rapid resurgence of syphilis in Japan after the COVID-19 pandemic: A descriptive study.
    PLoS One. 2024;19:e0298288.
    PubMed         Abstract available
    
33. RENZI E, Baccolini V, Covelli A, Siena LM, et al
    Keeping university open did not increase the risk of SARS-CoV-2 acquisition: A test negative case-control study among students.
    PLoS One. 2024;19:e0301215.
    PubMed         Abstract available
    
34. CANGUSSU LR, Do Nascimento JAS, de Barros IRP, Cavalcanti RL, et al
    Effects of primary health care and socioeconomic aspects on the dispersion of COVID-19 in the Brazilian Northeast: Ecological study of the first pandemic wave.
    PLoS One. 2024;19:e0296837.
    PubMed         Abstract available
    
35. BRAY LA, Jervis LL, Janitz AE, Ross L, et al
    Toward trustworthy COVID-19 interventions: Building vaccine trust through community-university partnerships.
    PLoS One. 2024;19:e0300872.
    PubMed         Abstract available
    
36. XUE J, Zhou X, Yang J, Niu A, et al
    Comparative study on differential expression analysis methods for single-cell RNA sequencing data with small biological replicates: Based on single-cell transcriptional data of PBMCs from COVID-19 severe patients.
    PLoS One. 2024;19:e0299358.
    PubMed         Abstract available
    
37. BLAKE L, Tucker P, Vanderloo LM
    Mothers’ perspectives of the barriers and facilitators to reducing young children’s screen time during COVID-19: A reddit content analysis.
    PLoS One. 2024;19:e0301089.
    PubMed         Abstract available
    
    
    Vaccine
38. KLUWER B, Gleditsch R, Rydland KM, Mamelund SE, et al
    Higher educational attainment associated with higher confidence in influenza vaccination in Norway.
    Vaccine. 2024 Mar 21:S0264-410X(24)00338-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
39. VOLKMANN AM, Goldin S, McMurren B, Gapare C, et al
    Leveraging seasonal influenza health worker vaccination programmes for COVID-19 vaccine Introduction: A global qualitative analysis.
    Vaccine. 2024 Mar 25:S0264-410X(23)01490-1. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
40. BIEGUS J, Szenborn L, Zymlinski R, Zakliczynski M, et al
    The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure.
    Vaccine. 2024 Mar 25:S0264-410X(24)00366-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
41. DALEY MF, Reifler LM, Shoup JA, Glanz JM, et al
    Influenza vaccination accuracy among adults: Self-report compared with electronic health record data.
    Vaccine. 2024 Mar 25:S0264-410X(24)00339-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
    Virus Res
42. KUZIKOV M, Reinshagen J, Wycisk K, Corona A, et al
    Drug repurposing screen to identify inhibitors of the RNA polymerase (nsp12) and helicase (nsp13) from SARS-CoV-2 replication and transcription complex.
    Virus Res. 2024;343:199356.
    PubMed         Abstract available
    
43. GLENET M, Lebreil AL, N’Guyen Y, Meyer I, et al
    Structural impact of a new spike Y170W mutation detected in early emerging SARS-CoV-2 Omicron variants in France.
    Virus Res. 2024;343:199354.
    PubMed         Abstract available

#Coronavirus Disease Research #References (by Amedeo.com, March 24 ’24)

1. REISDORFF EJ, Johnston MM, Lall MD, Lu DW, et al
   Prospective validity evidence for the abbreviated emergency medicine Copenhagen Burnout Inventory.
   Acad Emerg Med. 2024 Mar 17. doi: 10.1111/acem.14892.
   PubMed         Abstract available
   
2. JOHARI F, Verma R
   Paxlovid for nonhospitalized patients with COVID-19.
   Acad Emerg Med. 2024 Mar 22. doi: 10.1111/acem.14896.
   PubMed        
   
   
   Antiviral Res
3. MOON C, Porges E, Roberts A, Bacon J, et al
   A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication.
   Antiviral Res. 2024 Mar 14:105859. doi: 10.1016/j.antiviral.2024.105859.
   PubMed         Abstract available
   
   
   BMJ
4. MCKEEVER V
   Long covid and myalgic encephalomyelitis/chronic fatigue syndrome are overlapping conditions.
   BMJ. 2024;384:q613.
   PubMed        
   
   
   Clin Infect Dis
5. GUPTA A, Hughes MD, Cruz JL, Avihingsanon A, et al
   Adverse Pregnancy Outcomes among HIV-infected Women Taking Isoniazid Preventive Therapy During the First Trimester.
   Clin Infect Dis. 2023 Sep 28:ciad583. doi: 10.1093.
   PubMed         Abstract available
   
6. GOHEEN MM
   Growing Up COVID.
   Clin Infect Dis. 2024;78:496-498.
   PubMed        
   
7. STIER EA, Jain M, Joshi H, Darragh TM, et al
   Two-Year Incidence and Cumulative Risk and Predictors of Anal High-Grade Squamous Intraepithelial Lesions (anal precancer) among Women with HIV.
   Clin Infect Dis. 2023 Oct 8:ciad614. doi: 10.1093.
   PubMed         Abstract available
   
8. CARAZO S, Guay CA, Skowronski DM, Amini R, et al
   Influenza hospitalization burden by subtype, age, comorbidity and vaccination status: 2012/13 to 2018/19 seasons, Quebec, Canada.
   Clin Infect Dis. 2023 Oct 11:ciad627. doi: 10.1093.
   PubMed         Abstract available
   
9. KOLBERG L, Khanijau A, van der Velden FJS, Herberg J, et al
   Raising AWaRe-ness of Antimicrobial Stewardship Challenges in Pediatric Emergency Care: Results from the PERFORM Study Assessing Consistency and Appropriateness of Antibiotic Prescribing Across Europe.
   Clin Infect Dis. 2024;78:526-534.
   PubMed         Abstract available
   
   
   Graefes Arch Clin Exp Ophthalmol
10. VON DER BURCHARD C, Gruben A, Roider J
    Optical coherence tomography angiography suggests choriocapillaris perfusion deficit as etiology of acute macular neuroretinopathy.
    Graefes Arch Clin Exp Ophthalmol. 2024 Mar 21. doi: 10.1007/s00417-024-06436.
    PubMed         Abstract available
    
    
    Infect Control Hosp Epidemiol
11. SCHMITZ E, Anderson L, Hatas G, Stevens L, et al
    Population and hospital-level COVID-19 measures are associated with increased risk of hospital-onset COVID-19.
    Infect Control Hosp Epidemiol. 2024 Mar 18:1-3. doi: 10.1017/ice.2024.
    PubMed         Abstract available
    
12. JOSHI S, Arshad S, Lindsay A, Heinonen J, et al
    Control of SARS-CoV-2 infection in skilled nursing facilities in Detroit, Michigan: a model for emerging infectious diseases.
    Infect Control Hosp Epidemiol. 2024 Mar 20:1-3. doi: 10.1017/ice.2024.
    PubMed         Abstract available
    
    
    J Infect
13. SUN L, Man Q, Zhang H, Xia S, et al
    Strong cross immune responses against sarbecoviruses but not merbecoviruses in SARS-CoV-2 BA.5/BF.7-infected individuals with or without inactivated COVID-19 vaccination.
    J Infect. 2024;88:106138.
    PubMed        
    
14. SALMAN M, Rana MS, Usman M, Tahir M, et al
    Re-emergence of Diphtheria after COVID-19 Pandemic in Pakistan: time to consider booster vaccination strategies.
    J Infect. 2024 Mar 19:106141. doi: 10.1016/j.jinf.2024.106141.
    PubMed        
    
    
    J Med Virol
15. ROBERTS SC, Jolley SE, Beaty LE, Aggarwal NR, et al
    Association between monoclonal antibody therapy, vaccination, and longer-term symptom resolution after acute COVID-19.
    J Med Virol. 2024;96:e29541.
    PubMed         Abstract available
    
16. DE AGUIRRE PM, Carlos S, Pina-Sanchez M, Mbikayi S, et al
    High pre-Delta and early-Omicron SARS-CoV-2 seroprevalence detected in dried blood samples from Kinshasa (D.R. Congo).
    J Med Virol. 2024;96:e29529.
    PubMed         Abstract available
    
17. TRANTER E, Frentsch M, Hutter-Kronke ML, Vuong GL, et al
    Comparable CD8(+) T-cell responses to SARS-CoV-2 vaccination in single-cell transcriptomics of recently allogeneic transplanted patients and healthy individuals.
    J Med Virol. 2024;96:e29539.
    PubMed         Abstract available
    
18. ZHOU J, Zhou Y, Wei XF, Fan L, et al
    TRIM6 facilitates SARS-CoV-2 proliferation by catalyzing the K29-typed ubiquitination of NP to enhance the ability to bind viral genomes.
    J Med Virol. 2024;96:e29531.
    PubMed         Abstract available
    
19. JITOBAOM K, Peerapen P, Boonyuen U, Meewan I, et al
    Identification of inositol monophosphatase as a broad-spectrum antiviral target of ivermectin.
    J Med Virol. 2024;96:e29552.
    PubMed         Abstract available
    
20. HUANG M, Cui T, Liu S, Su X, et al
    Blended BA.5 infection within 8 days after a boosted bivalent mRNA vaccination strengthens and lengthens the host immunity.
    J Med Virol. 2024;96:e29544.
    PubMed         Abstract available
    
21. ZHANG H, Guo H
    Optimization of a DNA-launched SARS-CoV-2 replicon with RNA splicing inhibitor Isoginkgetin.
    J Med Virol. 2024;96:e29547.
    PubMed         Abstract available
    
22. ZHA G, Chen Z, Wu N, Huang T, et al
    Clinical characteristics and immunogenicity after Omicron breakthrough infection in patients with chronic hepatitis B infection: A longitudinal observational study.
    J Med Virol. 2024;96:e29548.
    PubMed         Abstract available
    
23. KUO YM, Kang CM, Lai ZY, Huang TY, et al
    Temporal changes in biomarkers of neutrophil extracellular traps and NET-promoting autoantibodies following adenovirus-vectored, mRNA, and recombinant protein COVID-19 vaccination.
    J Med Virol. 2024;96:e29556.
    PubMed         Abstract available
    
24. ZEDAN HT, Smatti MK, Al-Sadeq DW, Al Khatib HA, et al
    SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.
    J Med Virol. 2024;96:e29527.
    PubMed         Abstract available
    
25. FU X, Wang Z, Chen B, Sun H, et al
    Detection of SARS-CoV-2 virus in middle ear effusions and its association with otitis media with effusion.
    J Med Virol. 2024;96:e29545.
    PubMed         Abstract available
    
26. FROHLICH GC, Gregianini TS, Pinheiro FG, Nascimento R, et al
    Resurgence of human respiratory syncytial virus during COVID-19 pandemic in Southern Brazil.
    J Med Virol. 2024;96:e29551.
    PubMed         Abstract available
    
27. HUNG KC, Lin HJ, Chen IW
    New-onset neurodegenerative diseases following SARS-CoV-2 infection: An analysis of prediction interval.
    J Med Virol. 2024;96:e29563.
    PubMed        
    
28. WANG A
    Integrating Frechet distance and AI reveals the evolutionary trajectory and origin of SARS-CoV-2.
    J Med Virol. 2024;96:e29557.
    PubMed         Abstract available
    
29. HUANG J, Qiu Y, Luo L, Wu J, et al
    Long-term immunogenicity and safety of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine.
    J Med Virol. 2024;96:e29542.
    PubMed         Abstract available
    
30. BROGNA C, Montano L, Zanolin ME, Bisaccia DR, et al
    A retrospective cohort study on early antibiotic use in vaccinated and unvaccinated COVID-19 patients.
    J Med Virol. 2024;96:e29507.
    PubMed         Abstract available
    
31. ZHENG L, Wang H, Liu X, Xu C, et al
    A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant.
    J Med Virol. 2024;96:e29528.
    PubMed         Abstract available
    
    
    J Virol
32. YANG Y-L, Wang B, Li W, Cai H-L, et al
    Functional dissection of the spike glycoprotein S1 subunit and identification of cellular cofactors for regulation of swine acute diarrhea syndrome coronavirus entry.
    J Virol. 2024 Mar 19:e0013924. doi: 10.1128/jvi.00139.
    PubMed         Abstract available
    
33. MAI F, Bergmann W, Reisinger EC, Muller-Hilke B, et al
    The varying extent of humoral and cellular immune responses to either vector- or RNA-based SARS-CoV-2 vaccines persists for at least 18 months and is independent of infection.
    J Virol. 2024 Mar 19:e0191223. doi: 10.1128/jvi.01912.
    PubMed         Abstract available
    
34. WANG T, Hu L, Li R, Ren H, et al
    Hyperoside inhibits EHV-8 infection via alleviating oxidative stress and IFN production through activating JNK/Keap1/Nrf2/HO-1 signaling pathways.
    J Virol. 2024 Mar 19:e0015924. doi: 10.1128/jvi.00159.
    PubMed         Abstract available
    
35. WANG X, Tong W, Yang X, Zhai H, et al
    RBM14 inhibits the replication of porcine epidemic diarrhea virus by recruiting p62 to degrade nucleocapsid protein through the activation of autophagy and interferon pathway.
    J Virol. 2024;98:e0018224.
    PubMed         Abstract available
    
    
    JAMA
36. HARRIS E
    COVID-19 Infection Tied to Slight Cognitive Deficits.
    JAMA. 2024 Mar 22. doi: 10.1001/jama.2024.2087.
    PubMed        
    
37. HARRIS E
    COVID-19 Associated With Higher Risk of Autoimmune Diseases.
    JAMA. 2024 Mar 22. doi: 10.1001/jama.2024.2092.
    PubMed        
    
38. LU Y, Matuska K, Nadimpalli G, Ma Y, et al
    Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults.
    JAMA. 2024;331:938-950.
    PubMed         Abstract available
    
39. NIELSEN FM, Klitgaard TL, Siegemund M, Laake JH, et al
    Lower vs Higher Oxygenation Target and Days Alive Without Life Support in COVID-19: The HOT-COVID Randomized Clinical Trial.
    JAMA. 2024 Mar 19:e242934. doi: 10.1001/jama.2024.2934.
    PubMed         Abstract available
    
40. SCHWARTZSTEIN RM
    Oxygen Supplementation in COVID-19-How Much Is Enough?
    JAMA. 2024 Mar 19. doi: 10.1001/jama.2024.2935.
    PubMed        
    
41. GRAETZ N, Hepburn P, Gershenson C, Porter SR, et al
    Examining Excess Mortality Associated With the COVID-19 Pandemic for Renters Threatened With Eviction.
    JAMA. 2024;331:592-600.
    PubMed         Abstract available
    
    
    MMWR Morb Mortal Wkly Rep
42. WILLIAMS SL, Smith DJ, Benedict K, Ahlers JR, et al
    Surveillance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis During the COVID-19 Pandemic – United States, 2019-2021.
    MMWR Morb Mortal Wkly Rep. 2024;73:239-244.
    PubMed         Abstract available
    
    
    Nature
43. KIM SE
    Four years on: the career costs for scientists battling long COVID.
    Nature. 2024;627:689-691.
    PubMed        
    
44. LOPEZ LLOREDA C
    COVID’s toll on the brain: new clues emerge.
    Nature. 2024 Mar 20. doi: 10.1038/d41586-024-00828.
    PubMed        
    
45. LENHARO M
    Google AI could soon use a person’s cough to diagnose disease.
    Nature. 2024 Mar 21. doi: 10.1038/d41586-024-00869.
    PubMed        

#Coronavirus Disease Research #References (by Amedeo.com, March 17 ’24)

1. SHELTON J, Zotow E, Smith L, Johnson SA, et al
   25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysis.
   BMJ. 2024;384:e076962.
   PubMed         Abstract available
   
2. WILKINSON E
   Covid inquiry: What we have learnt about Wales’s response?
   BMJ. 2024;384:q608.
   PubMed        
   
   
   Clin Infect Dis
3. SHRESTHA NK, Burke PC, Nowacki AS, Gordon SM, et al
   Effectiveness of the 2023-2024 Formulation of the Coronavirus Disease 2019 mRNA Vaccine.
   Clin Infect Dis. 2024 Mar 11:ciae132. doi: 10.1093.
   PubMed         Abstract available
   
4. ROWAN CM, LaBere B, Young CC, Zambrano LD, et al
   Pre-existing Immunocompromising Conditions and Outcomes of Acute COVID-19 Patients Admitted for Pediatric Intensive Care.
   Clin Infect Dis. 2024 Mar 11:ciae133. doi: 10.1093.
   PubMed         Abstract available
   
5. ROMINE JK, Li H, Coughlin MM, Jones JM, et al
   Hybrid immunity and SARS-CoV-2 antibodies: results of the HEROES-RECOVER prospective cohort study.
   Clin Infect Dis. 2024 Mar 11:ciae130. doi: 10.1093.
   PubMed         Abstract available
   
6. HAYDEN MK, El Mikati IK, Hanson KE, Englund JA, et al
   Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing.
   Clin Infect Dis. 2024 Mar 15:ciae121. doi: 10.1093.
   PubMed         Abstract available
   
   
   Infect Control Hosp Epidemiol
7. NAKAGAWA M, Fujishiro Y, Doi Y, Yamakami J, et al
   Differences in the incidence of nosocomial-onset COVID-19 among hospitalized patients with exposure to SARS-CoV-2.
   Infect Control Hosp Epidemiol. 2024 Mar 14:1-3. doi: 10.1017/ice.2024.
   PubMed         Abstract available
   
8. LI H, Sewell DK, Herman T, Pemmeraju SV, et al
   Comparing multiple infection control measures in a nursing home setting: a simulation study.
   Infect Control Hosp Epidemiol. 2024 Mar 15:1-8. doi: 10.1017/ice.2024.
   PubMed         Abstract available
   
   
   Int J Infect Dis
9. BANDA L, Ho A, Kasenda S, Read JM, et al
   Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study.
   Int J Infect Dis. 2023;137:118-125.
   PubMed         Abstract available
   
10. HOSOZAWA M, Hori M, Hayama-Terada M, Arisa I, et al
    Prevalence and risk factors of post-coronavirus disease 2019 condition among children and adolescents in Japan: A matched case-control study in the general population.
    Int J Infect Dis. 2024 Mar 12:107008. doi: 10.1016/j.ijid.2024.107008.
    PubMed         Abstract available
    
    
    J Infect
11. MORENO-TORRES V, Martinez-Urbistondo M, Calderon-Parra J, de Mendoza C, et al
    COVID-19 Mortality Amongst the Immunosuppresed.
    J Infect. 2024 Mar 11:106137. doi: 10.1016/j.jinf.2024.106137.
    PubMed        
    
    
    J Med Virol
12. 
    Correction to “Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-word setting”.
    J Med Virol. 2024;96:e29518.
    PubMed        
    
13. ZHENG Y, Feng J, Song Y, Yu Y, et al
    Design and synthesis of APN and 3CLpro dual-target inhibitors based on STSBPT with anticoronavirus activity.
    J Med Virol. 2024;96:e29512.
    PubMed         Abstract available
    
14. ROJO-ALBA S, Martinez ZP, Gonzalez-Alba JM, Boga JA, et al
    Respiratory syncytial virus incidence and typing in the last six seasons in the north of Spain (Asturias). Genetic characterization during the SARS-CoV-2 pandemic.
    J Med Virol. 2024;96:e29499.
    PubMed         Abstract available
    
15. YEH LT, Chan CH, Wang YH, Lee CY, et al
    Exploring the incidence of peripheral arterial occlusive disease following COVID-19 infection: A retrospective cohort study.
    J Med Virol. 2024;96:e29519.
    PubMed         Abstract available
    
16. TAI CG, Haviland MJ, Kissler SM, Lucia RM, et al
    Low antibody levels associated with significantly increased rate of SARS-CoV-2 infection in a highly vaccinated population from the US National Basketball Association.
    J Med Virol. 2024;96:e29505.
    PubMed         Abstract available
    
17. LEE C, Greenwood DC, Master H, Balasundaram K, et al
    Prevalence of orthostatic intolerance in long covid clinic patients and healthy volunteers: A multicenter study.
    J Med Virol. 2024;96:e29486.
    PubMed         Abstract available
    
    
    J Travel Med
18. QUIGLEY AL, Kunasekaran M, Stone H, Honeyman D, et al
    The impact of the cruise ship coral princess on COVID-19 transmission in regional Western Australia in 2022.
    J Travel Med. 2024 Mar 12:taae044. doi: 10.1093.
    PubMed        
    
    
    J Virol
19. LIU D, Cruz-Cosme R, Wu Y, Leibowitz J, et al
    2-Bromopalmitate depletes lipid droplets to inhibit viral replication.
    J Virol. 2024 Mar 15:e0017124. doi: 10.1128/jvi.00171.
    PubMed         Abstract available
    
20. BABOT M, Boulard Y, Agouda S, Pieri L, et al
    Oligomeric assembly of the C-terminal and transmembrane region of SARS-CoV-2 nsp3.
    J Virol. 2024 Mar 14:e0157523. doi: 10.1128/jvi.01575.
    PubMed         Abstract available
    
21. HEINDL MR, Rupp A-L, Schwerdtner M, Bestle D, et al
    ACE2 acts as a novel regulator of TMPRSS2-catalyzed proteolytic activation of influenza A virus in airway cells.
    J Virol. 2024 Mar 12:e0010224. doi: 10.1128/jvi.00102.
    PubMed         Abstract available
    
    
    JAMA
22. ANDERER S
    CDC Recommends Additional COVID-19 Booster for Older Adults.
    JAMA. 2024 Mar 13. doi: 10.1001/jama.2024.2071.
    PubMed        
    
23. MCKENZIE C, Moore L, Borthwick M
    Vitamin C for Patients Hospitalized With COVID-19.
    JAMA. 2024;331:886.
    PubMed        
    
24. ADHIKARI NKJ, Lamontagne F
    Vitamin C for Patients Hospitalized With COVID-19-Reply.
    JAMA. 2024;331:886-887.
    PubMed        
    
25. HARRIS E
    Virtual Group Exercise Program Improved Long COVID Symptoms.
    JAMA. 2024;331:822.
    PubMed        
    
    
    Lancet
26. 
    Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden
    Lancet. 2024 Mar 8:S0140-6736(24)00476-8. doi: 10.1016/S0140-6736(24)00476.
    PubMed         Abstract available
    
27. SHAWE-TAYLOR M, Greenwood D, Hobbs A, Dowgier G, et al
    Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.
    Lancet. 2024 Mar 11:S0140-6736(24)00316-7. doi: 10.1016/S0140-6736(24)00316.
    PubMed        
    
28. PARHIZ H, Atochina-Vasserman EN, Weissman D
    mRNA-based therapeutics: looking beyond COVID-19 vaccines.
    Lancet. 2024 Mar 7:S0140-6736(23)02444-3. doi: 10.1016/S0140-6736(23)02444.
    PubMed         Abstract available
    
    
    Lancet Infect Dis
29. ZHANG R, Hung IF
    Bivalent (Omicron BA.5/ancestral) recombinant spike protein vaccine: a promising booster.
    Lancet Infect Dis. 2024 Mar 6:S1473-3099(24)00156.
    PubMed        
    
30. BENNETT C, Woo W, Bloch M, Cheung K, et al
    Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
    Lancet Infect Dis. 2024 Mar 6:S1473-3099(24)00077.
    PubMed         Abstract available
    
31. BILSEN MP, Conroy SP, Schneeberger C, Platteel TN, et al
    A reference standard for urinary tract infection research: a multidisciplinary Delphi consensus study.
    Lancet Infect Dis. 2024 Mar 5:S1473-3099(23)00778.
    PubMed         Abstract available
    
    
    MMWR Morb Mortal Wkly Rep
32. YOUSAF AR, Lindsey KN, Wu MJ, Shah AB, et al
    Notes from the Field: Surveillance for Multisystem Inflammatory Syndrome in Children – United States, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:225-228.
    PubMed        
    
    
    Nature
33. MERIGGI NF, Voors M, Levine M, Ramakrishna V, et al
    Last-mile delivery increases vaccine uptake in Sierra Leone.
    Nature. 2024 Mar 13. doi: 10.1038/s41586-024-07158.
    PubMed         Abstract available
    
34. BUTTENHEIM A, Thirumurthy H
    Mobile delivery of COVID-19 vaccines improved uptake in rural Sierra Leone.
    Nature. 2024 Mar 13. doi: 10.1038/d41586-023-03186.
    PubMed        
    
35. KOZLOV M
    Massive public-health experiment sends vaccination rates soaring.
    Nature. 2024 Mar 13. doi: 10.1038/d41586-024-00730.
    PubMed        
    
    
    Science
36. CROSS RW, Woolsey C, Chu VC, Babusis D, et al
    Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus.
    Science. 2024;383:eadk6176.
    PubMed         Abstract available
    
37. 
    Erratum for the Research Article “The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic” by M. Worobey et al.
    Science. 2024;383:eadp1133.
    PubMed        

#Coronavirus Disease Research #References (by Amedeo.com, March 10 ’24)

1. KIM MS, Lee H, Lee SW, Kwon R, et al
   Long-Term Autoimmune Inflammatory Rheumatic Outcomes of COVID-19 : A Binational Cohort Study.
   Ann Intern Med. 2024 Mar 5. doi: 10.7326/M23-1831.
   PubMed         Abstract available
   
2. GRANWEHR BP
   In mild to moderate COVID-19, VV116 safely reduced time to sustained clinical symptom resolution.
   Ann Intern Med. 2024 Mar 5. doi: 10.7326/J24-0006.
   PubMed         Abstract available
   
3. CAI J, Pirzada A, Baldoni PL, Heiss G, et al
   Cumulative All-Cause Mortality in Diverse Hispanic/Latino Adults : A Prospective, Multicenter Cohort Study.
   Ann Intern Med. 2024 Mar 5. doi: 10.7326/M23-1990.
   PubMed         Abstract available
   
   
   Antiviral Res
4. BANDYSZEWSKA M, Ambrozek-Latecka M, Hoser G, Grzanka M, et al
   SARS-CoV-2 virus-like particle variants alpha and delta mimic the native viruses in their differential inflammasome activating potential.
   Antiviral Res. 2024 Mar 5:105857. doi: 10.1016/j.antiviral.2024.105857.
   PubMed         Abstract available
   
5. WANG W, Wang S, Meng X, Zhao Y, et al
   A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2.
   Antiviral Res. 2024 Mar 4:105854. doi: 10.1016/j.antiviral.2024.105854.
   PubMed         Abstract available
   
6. KLEVANSKI M, Kim H, Heilemann M, Kuner T, et al
   Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A.
   Antiviral Res. 2024 Mar 4:105856. doi: 10.1016/j.antiviral.2024.105856.
   PubMed         Abstract available
   
7. SCHREIBER A, Rodner F, Oberberg N, Anhlan D, et al
   The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance.
   Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840.
   PubMed         Abstract available
   
8. NOBORI H, Baba K, Kuroda T, Baba K, et al
   Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
   Antiviral Res. 2024;224:105852.
   PubMed         Abstract available
   
   
   BMJ
9. WATTERSON A
   What we did not learn at the covid inquiry in Scotland: a gap analysis.
   BMJ. 2024;384:q491.
   PubMed        
   
10. 
    Analysis of peer reviewers’ response to invitations by gender and geographical region: cohort study of manuscripts reviewed at 21 biomedical journals before and during covid-19 pandemic.
    BMJ. 2024;384:q528.
    PubMed        
    
11. AGIUS RM
    UK workers during the pandemic: inadequate protection and, consequently, increased risk.
    BMJ. 2024;384:q508.
    PubMed        
    
    
    Clin Infect Dis
12. WENZEL RP
    Reflections on COVID-19: Solitude and Isolation.
    Clin Infect Dis. 2024 Mar 7:ciae099. doi: 10.1093.
    PubMed        
    
13. HUYGENS S, GeurtsvanKessel C, Gharbharan A, Bogers S, et al
    Clinical and Virological Outcome of Monoclonal Antibody Therapies Across Severe Acute Respiratory Syndrome Coronavirus 2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.
    Clin Infect Dis. 2024 Mar 6:ciae026. doi: 10.1093.
    PubMed         Abstract available
    
    
    Infect Control Hosp Epidemiol
14. GUSSIN GM, Singh RD, Gohil SK, Saavedra R, et al
    Impact of universal chlorhexidine bathing with or without COVID-19 intensive training on staff and resident COVID-19 case rates in nursing homes.
    Infect Control Hosp Epidemiol. 2024 Mar 5:1-4. doi: 10.1017/ice.2024.
    PubMed         Abstract available
    
    
    Int J Infect Dis
15. BOUWMANS P, Malahe SRK, Messchendorp AL, Vart P, et al
    Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: a nested case-control study.
    Int J Infect Dis. 2024 Feb 28:106990. doi: 10.1016/j.ijid.2024.106990.
    PubMed         Abstract available
    
16. REES C, Swift B, Haldar P
    State of art of the detection of M. tuberculosis during TB infection by blood tests using the phage technology.
    Int J Infect Dis. 2024 Mar 4:106991. doi: 10.1016/j.ijid.2024.106991.
    PubMed         Abstract available
    
17. AGUILAR TICONA JP, Xiao M, Li D, Nery JN, et al
    Corrigendum to “Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity: A prevalence survey” [International Journal of Infectious Diseases 139 (2024) 159-167].
    Int J Infect Dis. 2024;141:106964.
    PubMed        
    
    
    Intensive Care Med
18. SALVE G, Mongodi S, Mangiagalli M, Tintim Lobato C, et al
    Memories of ICU stay in patients admitted for severe COVID-19.
    Intensive Care Med. 2024 Mar 4. doi: 10.1007/s00134-024-07365.
    PubMed        
    
    
    J Infect
19. POWELL AA, Dowell AC, Moss P, Ladhani SN, et al
    Current state of COVID-19 in children: 4 years on.
    J Infect. 2024 Mar 1:106134. doi: 10.1016/j.jinf.2024.106134.
    PubMed         Abstract available
    
20. FATLY ZA, Betjes MGH, Dik WA, Fouchier RAM, et al
    Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations in kidney transplant recipients: results from a randomized controlled study.
    J Infect. 2024 Mar 1:106133. doi: 10.1016/j.jinf.2024.106133.
    PubMed         Abstract available
    
21. MEERAUS W, Joy M, Ouwens M, Taylor KS, et al
    AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study.
    J Infect. 2024 Feb 29:106129. doi: 10.1016/j.jinf.2024.106129.
    PubMed         Abstract available
    
22. HAYWARD G, Yu LM, Little P, Gbinigie O, et al
    Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.
    J Infect. 2024 Feb 29:106130. doi: 10.1016/j.jinf.2024.106130.
    PubMed         Abstract available
    
23. LIU P, Cai J, Tian H, Li J, et al
    Intra-host genetic diversity of SARS-CoV-2 Omicron variants in children.
    J Infect. 2024 Feb 29:106132. doi: 10.1016/j.jinf.2024.106132.
    PubMed        
    
    
    J Med Virol
24. CHEN IW, Lin HJ, Lin YT, Hung KC, et al
    Comment on “The association of sickle cell disorder with adverse outcomes in COVID-19 patients: A meta-analysis”.
    J Med Virol. 2024;96:e29495.
    PubMed        
    
25. LIU Y, Li M, Cui T, Chen Z, et al
    A superior heterologous prime-boost vaccination strategy against COVID-19: A bivalent vaccine based on yeast-derived RBD proteins followed by a heterologous vaccine.
    J Med Virol. 2024;96:e29454.
    PubMed         Abstract available
    
26. KIM JW, Lee JH, Kim HJ, Heo K, et al
    Empowering SARS-CoV-2 variant neutralization with a bifunctional antibody engineered with tandem heptad repeat 2 peptides.
    J Med Virol. 2024;96:e29506.
    PubMed         Abstract available
    
27. ZHANG R, Yan H, Zhou J, Yan G, et al
    Improved fluorescence-based assay for rapid screening and evaluation of SARS-CoV-2 main protease inhibitors.
    J Med Virol. 2024;96:e29498.
    PubMed         Abstract available
    
28. XIONG N, Sun Q
    Identifying COVID-19 subtypes by single-sample gene set enrichemnt analysis and providing guidance for sensitive drug selection.
    J Med Virol. 2024;96:e29497.
    PubMed         Abstract available
    
29. WU N, Chen Z, Zha G, Deng Z, et al
    Clinical and immunological features of COVID-19 in patients with anti-MDA5 dermatomyositis during the omicron wave in Chongqing, China.
    J Med Virol. 2024;96:e29493.
    PubMed         Abstract available
    
30. 
    Retraction: “Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial”.
    J Med Virol. 2024;96:e29509.
    PubMed         Abstract available
    
    
    J Travel Med
31. WANNIGAMA DL, Amarasiri M, Phattharapornjaroen P, Hurst C, et al
    Wastewater-based epidemiological surveillance of SARS-CoV-2 new variants BA.2.86 and offspring JN.1 in south and Southeast Asia.
    J Travel Med. 2024 Mar 4:taae040. doi: 10.1093.
    PubMed        
    
    
    J Virol
32. ZHENG T, Shen B, Bai Y, Li E, et al
    The PKA-CREB1 axis regulates coronavirus proliferation by viral helicase nsp13 association.
    J Virol. 2024 Mar 6:e0156523. doi: 10.1128/jvi.01565.
    PubMed         Abstract available
    
    
    JAMA
33. HARRIS E
    Better Outcomes When Kidney Damage Is From COVID-19.
    JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1574.
    PubMed        
    
34. HARRIS E
    HPV Vaccination Rates Stagnated During COVID-19 Pandemic.
    JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1569.
    PubMed        
    
35. HARRIS E
    Millions of US Children Experience Range of Long COVID Effects.
    JAMA. 2024;331:726.
    PubMed        
    
    
    Lancet Infect Dis
36. KOUTSAKOS M, Rockman S, Krammer F
    Is eradication of influenza B viruses possible?
    Lancet Infect Dis. 2024 Mar 4:S1473-3099(24)00132.
    PubMed        
    
    
    MMWR Morb Mortal Wkly Rep
37. MOLINE HL, Tannis A, Toepfer AP, Williams JV, et al
    Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season – New Vaccine Surveillance Network, October 2023-February 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:209-214.
    PubMed         Abstract available
    
    
    Zhonghua Jie He He Hu Xi Za Zhi
38. GAO HB, Zhang J
    [Analysis of prognostic factors in patients with COVID-19 infection].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:296-300.
    PubMed         Abstract available
    
39. GUO JW, Xiao Y
    [Impact of COVID-19 on the treatment of sleep medicine].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:292-296.
    PubMed         Abstract available
    
40. YU D, Huang WQ, Zhan YZ, Xiao GH, et al
    [Diaphragmatic dysfunction post-COVID-19 infection: report of two cases].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:244-248.
    PubMed         Abstract available
    
41. CHEN RX, Mai YL, Shen KN, Zhang T, et al
    [A case of follicular lymphoma with recurrent fever and pulmonary infiltrates].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:222-227.
    PubMed         Abstract available